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Abstract
Cocaine sensitization is associated with cocaine-induced hyperexcitability of
pyramidal projection neurons within the medial prefrontal cortex (mPFC). Such
hyperexcitability presumably results in increased glutamatergic input to reward-affiliated
brain regions such as the ventral tegemental area (VTA) and nucleus accumbens (NAc),
consequently facilitating drug-seeking behavior. Metabotropic glutamate receptor 5
(mGluR5) has been implicated in cocaine addiction and demonstrated to increase
neuronal excitability, therefore, the aim of the present study was to investigate the effect
of intra-mPFC mGluR5 manipulation on behavioral and neurochemical sensitization and
drug-seeking. Bilateral cannulae were implanted into the mPFC of male Sprague-Dawley
rats and mGluR5 antagonist MTEP (15 nmol/side) or saline was microinjected into the
region five minutes prior to a challenge cocaine injection. Our data showed that intramPFC mGluR5 blockade via MTEP prevented late, but not early, behavioral
sensitization. Further, intra-mPFC mGluR5 activation via DHPG (30 uM) increased
mPFC and NAc glutamate levels in sensitized animals during early and late withdrawal,
respectively. Finally, we observed a nonsignificant trend toward an MTEP-induced
reduction in drug-seeking following the presentation of a cocaine-associated cue in
animals that had been trained to self-administer cocaine. Taken together, our data suggest
mPFC mGluR5 plays a role in cocaine addiction, possibly through the modulation of
mPFC pyramidal neuronal excitability.
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Chapter 1. Introduction
History and Use of Cocaine
Cocaine was first isolated by the German chemist Albert Niemann in 1855,
however, archeological evidence suggests dried leaves of the Erythroxylon coca shrub
from which cocaine derives have been used for recreational and medicinal purposes by
indigenous South Americans as far back as 3000 BC (Boghdadi and Henning, 1997;
Johanson and Fischman, 1989; Warner, 1993). Cocaine gained popularity in Europe and
the United States in the late nineteenth century, and the drug became available in a wide
variety of products such as cigarettes, crystals, liquors, and the popular beverage Coca
Cola (Boghdadi and Henning, 1997; Das, 1993; Johanson and Fischman, 1989). Cocaine
was also added to a variety of therapeutic concoctions such as toothache, headache, and
stomach remedies (Johanson and Fischman, 1989).
Cocaine use in the United States came to a slow halt following the Harrison
Narcotic Act of 1914 (Boghdadi and Henning, 1997; Das and Laddu, 1993), making
cocaine far less accessible and tarnishing its image as a safe and useful substance. Further
dissuasion from cocaine use stemmed from increased public suspicion regarding its
toxicity (Johanson and Fischman, 1989). Because cocaine was present in such a wide
range of consumer products and medicines, there was great opportunity for adverse
effects to manifest and people were becoming skeptical of its benignity. Cocaine
remained largely absent from American popular culture until its resurgence in the late
seventies, which was augmented in part by the advent of a form of cocaine that could be
smoked (“crack”) (Warner, 1993).
While cocaine use has since declined slightly from its peak in the early eighties,
the National Survey on Drug Use and Health (NSDUH) estimates 1.9 million current
users in 2008, with 18-25 year olds being more likely to use than any other age group.
The 2008 NSDUH additionally suggests that 1.4 million Americans were dependent on
some form of cocaine, as determined by met Diagnostic and Statistical Manual of Mental
Disorders criteria. The 2008 Drug Abuse Warning Network report revealed that cocaine
was responsible for a fourth of the two million drug-related emergency room visits that
occurred that year. Finally, relapse rates hover around 60% for cocaine and 85% for
crack, suggesting that current treatments warrant some improvement (Statistical data
from National Institute of Drug Abuse website: www.nida.org).
Chemistry and Forms of Cocaine
Cocaine is an alkaloid that derives from the leaves of the Erythroxylon shrub, or
coca plant, which grows in the Andes mountains of South America (Johanson and
Fischman, 1989). Cocaine accounts for 1% of the weight of coca leaves and chewing the
leaves has been a common form of administration for millennia. However, low
gastrointestinal absorption and the relatively low concentration of cocaine in the leaves
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results in noticeable, but comparably minimal, effects (Warner, 1993). By contrast, when
combined with hydrochloric acid (cocaine hydrochloride), cocaine becomes a watersoluble salt that can consequently be injected or nasally insufflated, resulting in far
greater drug absorption. Cocaine hydrochloride may also be dissolved in water, mixed
with sodium bicarbonate, and heated, resulting in a solid substance that can be smoked,
most commonly in a glass pipe or cigarette (Khalsa et al., 1992). Heating this form of
cocaine produces a popping sound that earned it the street name “crack”. Due to its lower
cost and greater accessibility, crack has surpassed traditional cocaine in popularity and is
now the most commonly used form of the drug (Boghdadi and Henning, 1997).
Pharmacokinetics and Metabolism of Cocaine
Cocaine can be smoked, injected, or nasally insufflated. The drug reaches the
cerebral circulation in 6-8 seconds when smoked, 1-2 minutes when intravenously
injected, and 3-5 minutes when absorbed through the nasal mucous membranes
(Johanson and Fischman, 1989; Warner, 1993). Peak plasma levels are higher and
achieved more quickly when cocaine is smoked or injected than when it is snorted;
seconds for the former and up to an hour for the latter (Johanson and Fischman, 1989)
(Boghdadi and Henning, 1997). The delay is due, in part, to cocaine’s vasoconstrictive
action on the nasal mucosa that slows the drug’s absorption (Warner, 1993). However,
this impediment also results in the prolonged presence of cocaine in the plasma,
sometimes up to 6 hours, while subjects who intravenously administered the drug
reported a significant decrease in the effects just 40 minutes after the injection (Javaid et
al., 1978).
The plasma half-life of cocaine ranges from 30-90 minutes (Javaid et al., 1983)
(Warner, 1993), however, its clearance from other tissues can be substantially slower
(Johanson and Fischman, 1989). Approximately 95% of cocaine is metabolized into
benzoylecgonine, ecgonine methyl ester, or norcocaine (Warner, 1993). The vast
majority (80-90%) of cocaine is metabolized into ecgonine methyl ester and
benzoylecgonine via enzymatic and nonenzymatic hydrolysis, respectively (Johanson and
Fischman, 1989; Warner, 1993). The plasma half-lives of benzoylecgonine and ecgonine
methyl ester are four and seven hours, respectively, however they can remain in the urine
for up to two weeks. Benzoylecgonine urine concentrations are 50-100 times higher than
those of cocaine or ecgonine methyl ester, so the metabolite is consequently targeted in
cocaine screening tests, which most commonly employ gas chromatography/ mass
spectrometry (Boghdadi and Henning, 1997; Warner, 1993). A small amount of cocaine
is metabolized into norcocaine via N-demethylation in the liver (Warner, 1993). This
metabolite can be potentially toxic to individuals with cholinesterase deficiencies,
resulting in life-threatening complications (Hoffman et al., 1992).
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Pharmacodynamics of Cocaine
The two primary pharmacologic actions of cocaine are the blockade of sodium
channels and the prevention of monoamine reuptake (Boghdadi and Henning, 1997). The
blockade of fast sodium channels in neuronal and cardiac cells ultimately attenuates
depolarization and action potential conduction (Benowitz, 1993; Boghdadi and Henning,
1997). This may lead to arrhythmia, which is associated with stroke and sudden death
(Benchimol et al., 1978). Myocardial infarction can also be induced through cocaine’s
blockade of norepinephrine reuptake, which can lead to increased heart rate and blood
pressure. Cocaine’s sodium channel occlusion has resulted in its use as a topical
anesthetic. In the past, it was used most often in ophthalmological settings, but was later
found to induce corneal epithelial sloughing (Johanson and Fischman, 1989). Presently, it
is utilized almost exclusively as an anesthetic during respiratory tract surgeries in a 4%
concentration with very few adverse effects (Johanson and Fischman, 1989).
Virtually all drugs of abuse increase dopaminergic transmission in rewardassociated brain regions, such as the ventral tegmental area (VTA) and nucleus
accumbens (NAc). Cocaine prevents monoamine reuptake by blocking transporters on
presynaptic terminals, resulting in increases of a given neurotransmitter in the synaptic
cleft (Benowitz, 1993). Since brain areas such as the VTA and NAc have a high
concentration of dopamine transporters, cocaine increases dopamine in these regions and
it is this action that accounts for its addictive potential (Fleming et al., 1990).
Medical Consequences of Cocaine Use
Both sporadic and chronic cocaine use can lead to wide range of health conditions
(Boghdadi and Henning, 1997). In the central nervous system, strokes (Levine et al.,
1991) seizures (Dhuna et al., 1991), and movement disorders (Hegarty et al., 1991) can
occur in first-time users, as well as seasoned addicts who have never experienced any
cocaine-related complications in the past. Cocaine-induced cardiac problems are
numerous, including arrhythmia (Benchimol et al., 1978), endocarditis (Chambers et al.,
1987), myocardial infarction (Isner et al., 1986), cardiomyopathy (Om et al., 1992), and
ruptured aorta (Barth et al., 1986).
Pulmonary consequences can occur following any route of cocaine
administration, but are most likely to result from smoking crack cocaine (Boghdadi and
Henning, 1997). Respiratory complications include, but are not limited to, inhalation
injuries (Boghdadi and Henning, 1997), vascular abrasions and bleeding (Bailey et al.,
1994) (Murray et al., 1988), and edema (Hoffman and Goodman, 1989).
Gastrointestinal complications primarily result from cocaine’s vasoconstrictive
actions on gastric arteries (Boghdadi and Henning, 1997) and comprise gastroduodenal
ulcers (Kram et al., 1992), intestinal tears Freudenberger 1990 (Freudenberger et al.,
1990), and colitis (Brown et al., 1994).
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In the kidney, cocaine use can result in acute rhabdomyolysis, renal infarction,
and acute renal failure (Boghdadi and Henning, 1997; Merigian and Roberts, 1987)
(Kramer and Turner, 1993). Rhabdomyolysis, a condition whereby skeletal muscle
components such as myoglobin leak into the bloodstream and compromise renal function,
accounts for one fourth of cocaine-related emergency room cases (Boghdadi and
Henning, 1997). The vasoconstrictive action of cocaine and resultant muscle ischemia is
thought to be primarily responsible for this condition, however, excessive amounts of
cocaine may also induce direct muscle deterioration (Boghdadi and Henning, 1997;
Nolte, 1991).
Since cocaine easily and rapidly crosses the placenta, use during pregnancy can
have tragic effects on the fetus. These complications include spontaneous abortion
(Chasnoff et al., 1985), stillbirth, placenta previa (Chasnoff et al., 1989), congenitial
abnormalities (Handler et al., 1991), and premature birth (Handler et al., 1991). Once
born, the neonate may suffer seizures, tachycardia, and cocaine withdrawal (Boghdadi
and Henning, 1997; Burkett et al., 1990).
Cocaine possesses intense euphorigenic properties due to its ability to increase
dopamine in the reward circuit (discussed in greater detail later), but it also can result in
less pleasurable psychiatric conditions such as depression, agitation, psychosis, delirium
and delusions. In some cases, these altered psychiatric states can have devastating
consequences like accidents, suicide and homicide (Warner, 1993). Due to cocaineinduced impairments in judgment, users are also at risk for contracting sexually
transmitted diseases such as HIV. HIV transmission, along with hepatitis, is also
increased in intravenous cocaine users.
Euphorogenic Effects of Cocaine
As previously discussed, one of cocaine’s primary actions is monoamine
transporter blockade, which leads to increases in monamines (dopamine, norepinephrine,
and serotonin) in the synaptic cleft. While cocaine binds with five and three times greater
affinity to the serotonin and norepinephrine transporter, respectively, a large body of
evidence suggests the rewarding element of cocaine use derives from the drug’s effects
on the dopamine transporter (White and Kalivas, 1998). While data imply cocaine’s
action at the serotonin and norepinephrine transporters plays a significant role in setting
the stage for addiction (Steketee, 2003; White and Kalivas, 1998), experiments in which
these two transporter types were manipulated have not shown a relationship between their
function and euphoria or drug-seeking behavior (White and Kalivas 1998). By contrast,
dopamine transporter knockout mice do not exhibit locomotor sensitization (discussed in
the following section) in response to repeated cocaine (Giros et al., 1996). Furthermore,
dopamine release in the nucleus accumbens is a consequence of nearly all drugs of abuse
(Kauer, 2004).
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Animal Models of Addiction
The two most widely used methods for studying addiction are the contingent and
noncontingent models. In the noncontingent paradigm, cocaine is repeatedly administered
to the animal by the experimenter while in contingent paradigms, the animal is trained to
self-administer cocaine. Behavioral sensitization is the most commonly studied
phenomenon using the noncontingent method and refers to the increase in drug-induced
locomotor activity observed following repeated drug exposure. The majority of my
project focuses on sensitization, so it will be discussed in greater detail in the following
sections. In self-administration models, relapse (via reinstatement) or drug-seeking can be
measured. In self-administration experiments, laboratory animals are trained to respond
(lever-press, nose poke) to a cue in order to obtain an intravenous drug injection (Shaham
et al., 2003). Generally, animals are considered to have learned the task when they are
reliably responding at the appropriate times, however, specific goal criteria varies among
labs and experiments. After animals have learned, they either undergo extinction training
wherein responding only results in an intravenous saline injection, or return to their home
cages for a certain period of time (days to weeks) before being placed back in the selfadministration chambers. In the former and more common condition, the experimenter is
studying reinstatement; in the latter, drug-seeking is being assessed. Reinstatement,
considered by many to be the most valid model for relapse, consists of re-exposing the
extinguished animal to drug or presenting it with a cue previously associated with drug.
The animal is then again placed in the self-administration chamber and its response
activity is recorded (responses at this stage only deliver intravenous saline). The
overarching goal of most reinstatement studies is to determine whether various
pharmacological or environmental manipulations can reduce the risk of relapse. The goal
of drug-seeking experiments is generally the same, but the methodology differs in that the
animal does not learn to dissociate the self-administration chamber and the drug. The
downside of this is that the relapse-prevention medium under scrutiny may not need to be
as effective to produce a significant effect as it would if tested under a reinstatement
paradigm. However, evidence suggests that neuroadaptations occur in rodents following
extinguishment (Knackstedt et al., 2010) and such adaptations may result in a neural
landscape that differs significantly from that of an addicted individual. Consequently, a
relapse-prevention tool effective in one state may not generalize to another.
While the self-administration paradigm is currently considered the most valid
model in the addiction field, there has been a fair amount of debate regarding the validity
of sensitization. Perhaps the most common qualm is skepticism about whether the neural
underpinnings of sensitization parallel those that occur in addiction, however, a recent
review suggests substantial overlap between the two models (Steketee and Kalivas,
2011). Nonetheless, given the controversy, we decided to conduct a similar investigation
of the role mPFC mGluR5 in drug-seeking using the self-administration paradigm to
further corroborate both the role of mPFC mGluR5 in addiction as well as the relevance
of sensitization as a model of addiction.

5

Sensitization and Addiction
Behavioral sensitization to cocaine was first observed in 1932 and refers to the
increase in locomotor activity in response to cocaine following repeated cocaine exposure
(Steketee, 2003). Sensitization also occurs in response to other drugs of abuse, such as
amphetamine, nicotine, alcohol, and morphine (Robinson and Becker, 1986; Steketee and
Kalivas, 2011). The role of sensitization in addiction is presently controversial, however,
a good deal of evidence suggests common mechanisms mediate both processes
(Robinson and Berridge, 1993). There is also significant overlap between studies of
sensitization (Steketee and Kalivas, 2011) and those of reinstatement, a model considered
by many to validly depict relapse. It has additionally been shown that animals that exhibit
a strong sensitized response to a drug are more likely to relapse in a self-administration
paradigm (DeVries et al., 1998). Furthermore, cross-sensitization occurs between various
drugs of abuse, indicating sensitization derives from mechanisms characteristic of a
general addicted neural state (Steketee, 2003). Finally, both sensitization and addiction
share the qualities of longevity and susceptibility to individual differences (Tzschentke
and Schmidt, 2003). Addiction is a lifelong struggle and sensitization can be observed for
at least a year following the last exposure to a drug, suggesting sensitization is a
fundamental element of the resilient neuroadaptations that occur following repeated drug
use. Sensitization cannot be observed in every animal that is repeatedly exposed to a
drug, just like every individual who uses a drug will not become an addict. Factors such
as frequency of exposure, gender, age, and genetics influence sensitization and addiction
(Steketee and Kalivas, 2011).
Sensitization is generally divided into two stages: initiation and expression.
Initiation refers to the development of sensitization that occurs during the first few
exposures to the drug. The VTA is believed to play a significant role in this phase, seeing
as its inactivation prevents sensitization (Koob et al., 1981) and a number of early
modifications occur in this region following initial drug encounters (Kauer, 2004)
(Carlezon and Nestler, 2002; Thomas and Malenka, 2003). Expression can be further
divided into an early and late phase. Early expression is usually considered to be between
one and fourteen days from the last drug exposure while late expression is twenty-one
days and beyond following the last drug exposure. The nucleus accumbens is thought to
be the seat of lasting, drug-induced modifications that mediate the expression of
sensitization (Steketee and Kalivas, 2011).
Sensitization is typically measured through observing drug-induced locomotor
activity. Experiments usually consist of two groups of animals: one that receives
repeated, consecutive daily injections of drug (over x number of days; four, in our
studies) and one that receives an equivalent amount of saline for an equivalent amount of
time. After a certain time point following the last injection (our experiments look at
seven, fourteen, or twenty-one days), a challenge injection of drug is administered and
locomotor activity is measured for a certain amount of time (120 minutes in our lab). If
sensitization has occurred, a significantly greater amount of locomotor activity in the
drug group would be expected relative to saline controls.
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Brain Regions that Mediate Sensitization
Sensitization derives from alterations in the mesocorticolimbic (MCL), or reward,
circuit in the brain, consisting of the VTA, NAc and medial prefrontal cortex (mPFC).
The hippocampus, amygdala, laterodorsal tegmentum and the paraventricular nucleus are
additionally believed to be involved in sensitization, but probably via interaction with the
MCL circuit (Steketee and Kalivas, 2011). Dopaminergic projections from the VTA to
the NAc are perhaps the most crucial and well-studied element of the MCL circuit, as
they are the source of dopamine release in the NAc which, as previously mentioned, is
necessary for a drug to be subjectively evaluated as rewarding. The mPFC sends
glutamatergic projections to the VTA and the NAc (Sesack and Pickel, 1992), and the
importance of these projections in the regulation of addictive behavior is beginning to
come to light. The VTA and NAc also send reciprocal dopaminergic and GABAergic
projections, respectively, back to the mPFC (Oades and Halliday, 1987).
Lesion studies have been a useful, albeit first-pass, method for determining the
necessity of certain brain structures for the sensitization process. Inactivation of the VTA
and the NAc via radiofrequency or 6-hydroxydopamine diminished the sensitized
locomotor response to amphetamine (Koob et al., 1981), while ibotenic acid mPFC
lesions prevented behavioral cocaine sensitization(Li et al., 1999). The VTA has been
shown to be essential for the initiation of sensitization, while the NAc is deemed vital for
expression. Consistent with this, the mPFC can be subdivided into several regions that
each project predominantly to different brain structures and lesioning the mPFC area
projecting to the VTA prevents the initiation of sensitization, while lesioning the area
projecting to the NAc prevents expression (Pierce et al., 1998) (Steketee, 2003).
Cellular and Neurochemical Adaptations of Sensitization
A wide range of studies have demonstrated alterations in MCL brain structures
following repeated and acute cocaine exposure. These changes are believed to underlie
the unmanageable drug-seeking behavior observed in addicts, so an understanding of the
nature and temporal profile of these adaptations is critical to the development of
pharmacotherapies to treat addiction and prevent relapse. In the following sub-sections, I
will delineate documented changes in the VTA and the NAc. Since the basis of my
project rests on alterations in the mPFC, I will cover these in the next section.
Alterations in the VTA
At present, most noted alterations in the VTA are thought to be transient,
functioning primarily to mediate the early stages of sensitization (White and Kalivas,
1998). In support of this, dopamine levels in response to cocaine were found to be
initially elevated in sensitized rats but were indistinguishable from controls by fourteen
days post-exposure, however, behavioral sensitization could still be observed at this time
point (Kalivas and Duffy, 1993). Additionally, repeated intra-VTA administration of the
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dopamine re-uptake inhibitor GBR 12909 induced a sensitization to cocaine that was not
significantly different from that elicited in animals that received repeated cocaine,
suggesting enhanced VTA dopamine levels lead to sensitization (Cornish and Kalivas,
2001). Some relationships between dopamine receptors and sensitization in the VTA
have been observed, as well. Repeated intra-VTA injections of D1 receptor agonist SKF38393 induces cross-sensitization to a cocaine challenge in drug-naive rats (Pierce et al.,
1996). D1 receptor knock-out mice do not exhibit increased locomotor activity in
response to acute cocaine or sensitization to a higher dose of repeated cocaine, however,
it was ironically found that these mice displayed some (albeit nonsignificant)
sensitization to a lower dose of repeated cocaine (Karlsson et al., 2008). Finally, it has
been suggested that dopamine autoreceptors are less sensitive following cocaine
sensitization (Henry and White, 1991; White and Kalivas, 1998).
In addition to dopamine, elevated glutamate levels have been observed in
sensitized rats following a challenge cocaine injection administered twenty-one days
from the last sensitizing injection (Kalivas and Duffy, 1998). Glutamatergic transmission
in the VTA also appears to be augmented in sensitized rats, as evidenced by an increase
in neuronal firing following in vivo iontophoretic glutamate application (White et al.,
1995). Single-cell recording found VTA dopamine neurons to be more sensitive to
iontophoretically administered AMPA in sensitized versus saline animals (Zhang et al.,
1997). Increased levels of GluR1 and NMDAR1 were observed in the VTA of sensitized
rats (Fitzgerald et al., 1996) and intra-VTA injections of NMDAR antagonists block the
development of sensitization (Kalivas and Alesdatter, 1993). Data suggest a single
exposure to cocaine can potentiate synaptic AMPA currents on dopaminergic projection
neurons in the VTA (Ungless et al., 2001). This potentiation was demonstrated to last for
at least five, but not more than ten, days post-exposure, further corroborating a transient,
but necessary, role for the VTA in sensitization. This cocaine-induced increase in VTA
neuronal excitability was later found to depend on an inhibition of GABA-ergic synapses
that occurs following repeated cocaine, and could be prevented by the administration of
GABA agonist diazepam (Liu et al., 2005).
Taken together, these data suggest cocaine exposure induces a short-lived
plasticity in VTA dopaminergic output neurons that serves to increase input to target
regions, such as the NAc and mPFC. It is assumed that this transient increase in
dopaminergic transmission sets the stage for more lasting alterations in other rewardassociated brain structures.
Alterations in the NAc
In contrast to the VTA, cocaine-induced changes in the NAc are generally
believed to be longer lasting and may consequently play a greater role in the
unmanageable drug-seeking behavior observed in addiction. Several studies have
demonstrated AMPA alterations in the NAc following repeated cocaine exposure,
suggesting glutamatergic transmission in the NAc may play an important role in relapse.
An increase in locomotor activity was observed following intra-NAc microinjections of
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AMPA in sensitized animals relative to saline controls at 14 to 21 days withdrawal
(Pierce et al., 1996). Intra-NAc AMPA injections were also found to increase drugseeking behavior following a 28-day withdrawal period in sensitized rats (Suto et al.,
2004). Moreover, administration of an AMPA receptor antagonist was found to prevent
reinstatement when injected directly into the NAc (Cornish and Kalivas, 2000). Further,
an increase in GluR1 was observed in the NAc at 21 (but not 1) days cocaine withdrawal
in sensitized rats (Churchill et al., 1999). A later study found an increase in NMDA
receptor subunits NR1, NR2A, and NR2B at the delayed (21 day), but not immediate (1
day) time point (Schumann and Yaka, 2009). Finally, in NAc brain slices of sensitized
mice, a strong, AMPA-mediated long-term potentiation was observed following an
extended period of withdrawal, however, a single administration of cocaine rapidly
abolished this LTP and instead induced LTD (Kourrich et al., 2007).
Basal glutamate levels in the NAc are reduced following repeated cocaine (Baker
et al., 2002), while a challenge injection of cocaine was found to increase glutamate in
the NAc of sensitized animals relative to controls (Reid and Berger, 1996). This decrease
in basal glutamate is hypothesized to be due, in part, to a cocaine-induced disruption in
the function of the cysteine-glutamate anti-porter (Baker et al., 2003), which appears
plausible given that N-acetyl-cysteine can restore glutamate levels and prevent
reinstatement (Baker et al., 2003) and sensitization (Madayag et al., 2007). This data in
combination with the abovementioned AMPA receptor alterations suggest repeated
cocaine may induce a potentiated state in NAc synapses characterized by low glutamate
levels that serves to heighten contrast between a drug-abstinent and a drug-using state,
ultimately arming cocaine and its cues with greater influence over behavior (Steketee and
Kalivas, 2011).
Contrary to what one might expect, there does not appear to be a great deal of
cocaine-mediated dopamine alterations in the NAc, at least not relative to glutamate
(White and Kalivas, 1998). That said, dopamine increases in the NAc have been observed
following repeated cocaine (Kalivas and Duffy, 1990). A recent in vivo study
demonstrated via fast-scan cyclic voltammetry a cocaine-induced dopamine increase in
the NAc at 7 (but not 1) days withdrawal in sensitized rats (Addy et al., 2010). An
increased sensitivity in D1, but not D2, receptors in the NAc was observed at 7 and 30,
but not 60, days withdrawal in sensitized rats (Henry and White, 1991).
Involvement of the mPFC in Sensitization and Addiction
The mPFC is perhaps most colloquially associated with the famous case of
Phineas Gage, the nineteenth-century railway worker impaled through the skull by an
iron rod during an explosion. While the injury did not leave Gage with any lasting
impairments that were necessarily obvious to the casual observer, those who knew him
before the accident were unanimous in attesting that he was "no longer Gage". Prior to
the accident, Gage was reportedly careful, respectful, responsible, and business-minded--a demeanor that contrasted sharply with the reckless, crude and capricious disposition in
its place following the injury. Due to Gage's irresponsibility and inability to comprehend
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the exchange of currency, he spent the last decade of his life working for Barnum's circus
as an exhibit before he died from epilepsy in 1860, just twelve years after the accident.
Later examination of Gage's skull and those of other individuals who sustained similar
injuries revealed that the iron rod had most likely damaged Gage's prefrontal cortex, a
brain region now implicated in attention, working memory, reward processing, emotional
regulation, decision-making, impulsivity and inhibition, self-monitoring, and reversal
learning (Perry et al., 2011).
The human prefrontal cortex can be divided into medial, lateral, and orbital
regions (Perry et al., 2011). The medial region consists of the mPFC and anterior
cingulate cortex (ACC), and most cortically based cocaine abuse research in humans and
laboratory animals has focused on these regions. The lateral region of the PFC contains
distinct dorsal and ventral areas, as well as an inferior frontal junction (Ridderinkhof et
al., 2004). The lPFC sends and receives projections from premotor regions, which
ultimately originate in the motor cortex. This particular connectivity enables the lPFC to
influence behavior (Perry et al., 2011). The orbital region communicates with other areas
of the PFC and receives a wide range of sensory input.
In rodents, reciprocal connections exist between the mPFC and the NAc, VTA,
hypothalamus, hippocampus, amygdala, and other regions of the cortex (Dalley et al.,
2004; Perry et al., 2011). The rat mPFC is generally subdivided into dorsal and ventral
regions, with the former consisting of the precentral and anterior cingulate cortices and
the latter encompassing the prelimbic, infralimbic, medial orbital, and ventral orbital
regions. Unlike human mPFC, there does not appear to be a connectivity-based lPFC
correlate in rodents (Perry et al., 2011).
A growing base of human and laboratory animal studies point to a role of the
mPFC in cocaine addiction. Imaging studies in human addicts generally show an increase
in mPFC activity in response to or in expectation of cocaine, as well as following drugrelated cues (Goldstein and Volkow, 2011; Kufahl et al., 2008; Kufahl et al., 2005). In
rodents, mPFC lesions induced prior to repeated cocaine exposure prevented behavioral
sensitization (Li et al., 1999; Tzschentke and Schmidt, 1998) and cocaine injections
administered directly into the mPFC induced reinstatement in previously trained rats
(Park et al., 2002). As previously mentioned, obliteration of projections from the mPFC
to the NAc and VTA abolishes the expression and initiation of sensitization, respectively.
Taken together, these studies suggest the mPFC is essential in mediating the pathological
neuroadaptations that follow repeated cocaine.
Increasing amounts of data suggest neurochemical and electrophysiological
alterations occur in the mPFC following repeated cocaine exposure. Cocaine-mediated
mPFC dopamine levels are decreased during early sensitization but increased during late
sensitization and the reverse is true for glutamate levels (Williams and Steketee, 2005)
(Williams and Steketee, 2004). Relatedly, mPFC dopamine D2 and Group II
metabotropic glutamate receptor (mGluR) function was found to be reduced in rats
following repeated cocaine exposure (Beyer and Steketee, 2002; Xie and Steketee, 2009).
Additionally, a reduction in a Group II mGluR-mediated form of mPFC long-term
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depression (LTD) was observed in slices from rats repeatedly treated with cocaine
(Huang et al., 2007). Repeated cocaine was shown to alter the excitability of mPFC
pyramidal projection neurons during early and late withdrawal (Nasif et al., 2005), a
phenomenon the authors attributed to a decrease in membrane afterhyperpolarization and
an increase in L-type calcium channel activity (Ford et al., 2009; Hu, 2007). Together,
these studies suggest repeated cocaine induces early and late changes in the mPFC at the
neurotransmitter and cellular level that may ultimately alter mesolimbic transmission in a
manner that facilitates drug-seeking.
The role of the mPFC in executive function and its projections to addictionrelated regions like the VTA and NAc easily inspires the question of whether mPFC
dysfunction contributes to the loss-of-control over drug-seeking behavior seen in cocaine
addicts. Indeed, imaging studies have demonstrated an overall reduction in mPFC
function in addicts that can be remedied by drug exposure (Goldstein and Volkow, 2011).
Cocaine addicts showed a reduction in ACC activity relative to non-addicts during the
inhibitory-control-measuring Go/no-go task that correlated with poorer performance
(Kaufman et al., 2003). Further, cocaine addicts’ performance on the Stroop task, a
measure of overall mPFC function, was significantly lower than that of non-addicts
(Bolla et al., 2004) and pre-rehabilitation Stroop performance was found to predict
treatment outcome (Brewer et al., 2008; Goldstein and Volkow, 2011). Addicts’
deficiencies in the Go/no-go task and associated ACC hypoactivity could be corrected via
intravenous cocaine administration (Garavan et al., 2008). A similar rectification was
observed in the Stroop task following oral methylphenidate, a mild stimulant and DAT
antagonist (Goldstein et al., 2010). Cocaine addicts also appear to place less value on
non-drug rewards than non-addicts. For example, one study assessing this found
significantly less mPFC activation following the acquisition of a monetary reward in
addicts relative to controls (Goldstein et al., 2007). This is consistent with the relatively
large number of animal studies that demonstrate consistent selection of drug over nondrug rewards following repeated cocaine exposure, even when the non-drug rewards are
vital to the animal’s survival (Goldstein and Volkow, 2011). Taken together, this
evidence suggests repeated cocaine exposure results in an mPFC that is generally less
responsive to non-drug-related stimuli. If this is the case, treatments for cocaine addiction
designed to rectify cocaine-induced adaptations in the mPFC will be markedly more
promising than those that do not. Therefore, an understanding of the changes that occur in
the mPFC following repeated cocaine exposure is necessary. To gain such an
understanding, the mechanisms generating the marked polarization in mPFC excitability
between cocaine-related and unrelated scenarios should be uncovered. Given that
glutamate is the most pervasive and influential excitatory transmitter in the brain and
responsible for virtually all forms of plasticity, cocaine-induced alterations in the mPFC
glutamatergic system could conceivably lead to the lasting adaptations observed in
addicts.
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mPFC mGluR5 and Cocaine Addiction
As previously mentioned, mPFC glutamate levels are elevated in response to
cocaine during early withdrawal but return to baseline by late sensitization (Williams and
Steketee, 2004), suggesting that transient neurotransmitter changes may pave the way for
more permanent receptor alterations. Also mentioned earlier, studies have demonstrated
alterations in intrinsic pyramidal cell membrane properties (Nasif et al., 2005), ion
channel attributes (Ford et al., 2009), intracellular signaling (Bowers et al., 2004),
plasticity and Group II mGluR function following repeated cocaine exposure, suggesting
that long-term aberrations in mPFC excitability may predominantly be mediated via
changes in pyramidal projection cells. Consequently, when we set out to examine
potential cocaine-induced alterations in the mPFC glutamate system, we wanted to focus
on an element capable of effecting long-term changes in the cell.
mGluR5 is a member of the Group I mGluR family that also includes mGluR1.
Selectively located in corticolimbic regions, these Gq/G11-coupled receptors are
predominantly postsynaptic in the mPFC and generally serve to increase the excitability
of pyramidal neurons (Homayoun and Moghaddam, 2010; Kew and Kemp, 2005). There
are three primary reasons we were interested in the role of mGluR5 in cocaine-induced
mPFC alterations. First, mGluR5-null mice do not exhibit a sensitized locomotor
response to repeated cocaine (Chiamulera et al., 2001) and several studies have shown
that systemic mGluR5 antagonism prevents various facets of addiction in rodents, such as
reinstatement and sensitization (Martin-Fardon and Weiss, 2012); (Platt et al., 2008).
mGluR5 manipulation in reward-related brain regions has also affected addictive
behavior in rodents. For example, NAc mGluR5 blockade prevented and mGluR5
stimulation augmented cocaine-seeking behavior in a self-administration paradigm
(Wang et al., 2012). Another intriguing study that selectively knocked down mGluR5 in
D1-expressing neurons found that, while the affected mice still self-administered cocaine,
cue-induced reinstatement was impaired, leading the authors to surmise that mGluR5
activation on D1-expressing cells is necessary for the assignment of drug-related
importance to previously neutral stimuli (Novak et al., 2010).
Secondly, as previously mentioned, alterations in mPFC pyramidal cell
excitability and consequent changes in communication between the mPFC and the NAc
and VTA may contribute significantly to resilient drug-seeking behavior observed in
addicts. mGluR5 activation in thalamic, hippocampal, and nigral slices induces excitatory
postsynaptic potentials (EPSPs) and can lead to depolarization and increased firing
frequency (Awad et al., 2000; Homayoun and Moghaddam, 2010). Given that mPFC
projection neurons are hyperexcitable in response to cocaine following repeated cocaine
exposure, increased mGluR5 activation may contribute to this excitability.
Relatedly, our third reason for investigating mGluR5 is its purported modulatory
influence on neuronal firing. One study demonstrated that in vivo mGluR5 blockade via
antagonist MPEP in the mPFC prevented firing of roughly 50% of pyramidal neurons
(Homayoun and Moghaddam, 2006). The authors noted that MPEP preferentially
prevented the firing of cells that possessed a greater baseline firing level (Homayoun and
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Moghaddam, 2010), which they attested suggests mGluR5 may greatly influence the
overall regional output. As mentioned earlier, repeated cocaine exposure appears to result
in an mPFC that is hypoactive in response to non-drug stimuli, but hyperactive in
response to cocaine and its cues. That said, it is tempting to speculate that
pharmacological mGluR5 inhibition or modulation could ultimately attenuate the
influence of cocaine-related stimuli on drug-seeking behavior by reducing the excessive
firing of mPFC pyramidal neurons that ensues when an addicted individual encounters
such stimuli. Of clinical importance is the evidence suggesting mGluR5 modulation (not
antagonism) can fine tune elements of neuronal behavior without disrupting overall
transmission as would occur with ionotropic glutamate receptors, and such modulatory
drugs have shown promise in attenuating drug-seeking behavior in animals (Olive, 2009).
Consequently, further research into the role of mGluR5 in cocaine-induced neuroplastic
changes in the mPFC could lead to safe and effective pharmacotherapies for addiction.
Summary and Rationale
A functional mPFC enables an organism to effectively evaluate its environment
and make advantageous long-and short-term decisions. Evidence suggests repeated
cocaine leads to lasting changes in the mPFC and it is possible that these alterations are
responsible for addicts’ inability to regulate drug-seeking behavior. Adaptations in mPFC
pyramidal projection neurons can result in increased and decreased output to the VTA
and NAc in response to different types of stimuli. Given that glutamate is the most
abundant excitatory neurotransmitter in the brain and glutamatergic transmission
mediates the vast majority of neural plasticity, the current project focuses on the role of
mGluR5 in cocaine-induced mPFC neuroadaptations. mGluR5-null mice do not sensitize
to cocaine and mGluR5 antagonism has been repeatedly shown to reduce drug-seeking
behavior in laboratory animals. Further, mGluR5 stimulation has been demonstrated to
exert both a modulatory and an excitatory effect on the cell. Therefore, the current project
described below focuses on the effect of mPFC mGluR5 manipulations on cocaine
sensitization, self-administration, and neurotransmission in the mPFC, VTA and NAc.
We hypothesize mPFC mGluR5 activation contributes to pyramidal neuronal excitability
in sensitized animals and consequently influences behaviors and neurochemical profiles
associated with cocaine addiction.
Specific Aims
1) To examine the effects intra-mPFC mGluR5 manipulation on behavioral
sensitization to cocaine
2) To compare mPFC, VTA and NAc glutamate levels in response to intra-mPFC
mGluR5 stimulation in sensitized and control animals
3) To test the ability of mPFC mGluR5 antagonism to attenuate drug-seeking
behavior in a self-administration paradigm
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Chapter 2. Examination of a Role for Metabotropic Glutamate Receptor 5 in the
Medial Prefrontal Cortex in Cocaine Sensitization in Rats
Introduction
Chronic cocaine exposure has been shown to induce enduring neuroadaptations
that collectively result in the loss of control over drug-seeking behavior despite
multitudinous adverse consequences (Nestler, 2005). Behavioral sensitization, the
augmented locomotor response to cocaine following repeated exposure, has been shown
to have predictive validity for other indicators of addiction such as reinstatement,
possibly due to shared cocaine-induced modifications in neurocircuitry (Kalivas et al.,
1998; Robinson and Berridge, 1993; Steketee and Kalivas, 2011). The human medial
prefrontal cortex’s (mPFC) mediation of executive processes such as decision-making,
long-term planning, impulse control and outcome prediction, along with its dense
connectivity with the ventral tegmental area (VTA) and nucleus accumbens (NAc)
(D'Esposito and Chen, 2006) raised interest as to whether chronic cocaine exposure
induces alterations in this region. Indeed, studies subsequently found that neurochemical
and electrophysiological modifications (Huang et al., 2007; Nasif et al., 2005; Steketee,
2005) occur in the mPFC following sensitization. Of particular relevance to this study is
the evidence suggesting mPFC pyramidal neurons are hyperexcitable in response to
cocaine in sensitized animals (Nasif et al., 2005). Glutamatergic output from the mPFC to
the VTA and NAc is necessary for the initiation and expression of sensitization (Li et al.,
1999) respectively, and so it is plausible that heightened excitatory input to such limbic
structures represents a critical neuroadaptation that follows repeated cocaine exposure.
Consequently, an understanding of the mechanisms that induce physiological changes in
mPFC pyramidal cells could uncover avenues for the pharmacological prevention of
relapse.
In rodents, behavioral sensitization is observable as early as 1 day and at least as
late as 1 year post repeated cocaine exposure however the processes that give rise to it are
believed to change over time (Steketee, 2005). Cocaine-induced glutamate release in the
mPFC, for example, is elevated in sensitized rats 1 and 7 days following repeated cocaine
treatment, but returns to pre-drug exposure levels by 30 days post-exposure (Williams
and Steketee, 2004). These early changes in neurotransmitter levels may be critical
towards generating enduring alterations in mPFC responsivity. Indeed, mPFC Group II
metabotropic glutamate receptor function is reduced during late sensitization, which
should decrease inhibitory tone onto pyramidal neurons (Xie and Steketee, 2008). Thus,
this suggests that, in the mPFC, changes in glutamate levels may mediate early
sensitization, while glutamate receptor modifications may mediate late sensitization
(Steketee, 2005).
Group I metabotropic glutamate receptors (mGluRs) are primarily located
postsynaptically in the mPFC and serve to increase the excitability of pyramidal
projection neurons (Kew and Kemp, 2005). Group I mGluRs are Gq/G11-coupled and
contain two subtypes: mGluR1 and mGluR5 (Kew and Kemp, 2005)). mGluR5 knock-
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out mice do not exhibit cocaine sensitization and allosteric modulators of this receptor
have proven effective agents for preventing relapse to cocaine in animal studies (Kenny
et al., 2003; Olive, 2009). Additionally, stimulation of Group I mGluRs has been shown
to result in increased mPFC glutamate levels, which could, in turn, augment neuronal
excitability (Bandrowski et al., 2003; Melendez and Kalivas, 2003). Collectively, this
suggests that activation of mPFC Group I mGluRs may play a role in the behavioral
sensitization to cocaine. Therefore, to better understand the contribution of mPFC Group
I mGluRs to sensitization, experiments in this report tested whether repeated activation of
Group I mGluRs in the mPFC could induce cross-sensitization to cocaine and whether
this cross-sensitization was dependent on glutamatergic input from the mPFC to the
VTA. Furthermore, selective mGluR1 and mGluR5 antagonists were co-administered
with DHPG to determine which receptor was mediating cross-sensitization. Finally, the
effects of mPFC Group I mGluR antagonism on the initiation and expression of cocaine
sensitization were assessed.
Materials and Methods
Animals and Surgery
Male Sprague Dawley rats (Harlan, Indianapolis, IN) weighing 250-300 grams at
the time of surgery were housed under a 12-hour light/dark cycle and given free access to
food and water. Animals were anesthetized with a ketamine (80 mg/kg) and xylazine (6.0
mg/kg) cocktail (1.0 ml/kg) and placed in a stereotaxic apparatus (Kopf Instruments). An
incision was made in the scalp and the skin was pulled back to expose the skull. The area
was disinfected and burr holes were drilled into the skull. Three stainless steel screws that
would later anchor the dental acrylic (Jet-Set, Lang Dental, Germany) skullcap were
inserted into the burr holes. Guide cannulae were bilaterally implanted 1 mm above the
mPFC (A/P +3.2 mm, M/L ±0.6 mm, D/V -3.5 mm) and/or VTA (A/P -4.8 mm, M/L
±0.6 mm, D/V -7.4 mm) and dental acrylic was applied to secure them. Obturators (14
mm, 32 gauge stainless steel) were inserted into the cannulae to prevent their blockade.
Animals were housed individually following surgery and given one week to recover prior
to the start of experiments. All procedures were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals and
approved by the University of Tennessee Health Science Center Animal Resources
Advisory Committee.
Injections and Behavior
Animals were placed in activity chambers (45 x 24 x 19 cm) for 60 min prior to
injections to allow for proper adaptation. Drugs were administered into the mPFC and/or
VTA using a Sage syringe pump that held two 1 µl syringes attached to stainless steel
injectors (15 mm, 32 gauge) by PE 20 tubing and delivered drug at a rate of 0.5 µl/min
and a volume of 0.5 µl/side. Injectors were left in place for 20 s following injections and
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obturators were again inserted. In the experiments where a systemic injection followed a
microinjection, cocaine (15 mg/kg) or saline (1.0 ml/kg) was injected intraperitoneally 5
minutes after the microinjection. Animals were then placed back in the activity chambers
and locomotor activity was monitored through a Digiscan system (Accuscan, Columbus,
OH, USA) as previously described (Beyer and Steketee 2002). Data were collected for
120 min post-injection and organized into 15 min bins.
Histology and Statistics
Following studies, animals were heavily anesthetized with sodium pentothal (333
mg/kg) and perfused by intracardiac administration of phosphate-buffered saline (50 ml)
and 10% formaldehyde (50 ml). Brains were sectioned, mounted onto gelatin-coated
slides, stained with cresyl violet, and viewed through a light microscope to verify
cannulae and injector placement as determined by a rat brain atlas (Paxinos and Watson
1997). The time-course of the locomotor activity was analyzed using a two-way
(treatment and time) repeated measure (time) ANOVA. Multiple comparisons were made
using a modified least significant differences test (Milliken and Johnson 1984).
Drugs
Cocaine hydrochloride was purchased from Sigma Chemical Co. (St. Louis, MO,
USA). (s)-3, 5-DHPG (dihydroxyphenylglycine), MTEP hydrochloride (3((2-methyl-4thiazolyl)ethynyl)pyridine hydrochloride), CNQX (6-cyano-7-nitroquinoxaline-2,3dione), and YM 298198 hydrochloride (6-Amino-N-cyclohexyl-3-methylthiazolo[3,2a]benzimidazole-2-carboxamide hydrochloride) were all purchased from TOCRIS
Bioscience (Ellisville, MO, USA). All drugs were diluted with isotonic saline (0.9 units
sodium chloride). DHPG dosages were determined based on dose-response experiments
conducted in our lab. Dosages of MTEP, YM298198, and CNQX were selected based on
previous reports (Kumaresan et al., 2009; Titley et al., 2010; Torregrossa et al., 2008)
Experimental Design
Cross-Sensitization Experiments
Daily DHPG/Cocaine Test. This set of experiments was designed to measure
whether repeated intra-mPFC microinjections of the Group I mGluR agonist DHPG
could induce cross-sensitization to systemic cocaine in naïve animals. DHPG (15
nmol/side) or saline was microinjected into the mPFC once daily for 4 consecutive days.
Seven days following the final injection, a challenge injection of cocaine was delivered
(15 mg/kg, i.p.) and locomotor activity was monitored for 120 min.
DHPG+MTEP and DHPG+YM298198. This set of experiments determined
which of the two Group I mGluR subtypes (mGluR1 or mGluR5) was responsible for
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DHPG-induced cross-sensitization to cocaine. In the experiments examining the role of
mGluR5 in DHPG-induced cross-sensitization, DHPG (15 nmol/side) alone,
DHPG+Group I mGluR antagonist MTEP (15 nmol/side), MTEP (15 nmol/side) alone,
or saline was microinjected into the mPFC for 4 consecutive days and motor activity in
response to a systemically administered challenge injection of cocaine was assessed 7
days following the final microinjection.
In the experiments examining the role of mGluR1 in DHPG-induced crosssensitization, DHPG (15 nmol/side), DHPG+Group I mGluR1 antagonist YM298198 (15
nmol/side), YM298198 alone (15 nmol/side), or saline was microinjected into the mPFC
for 4 consecutive days and motor activity in response to a systemically administered
challenge injection of cocaine was assessed 7 days following the final microinjection.
Separate groups of animals were used for the MTEP and YM298198 experiments.
Daily Cocaine/DHPG Test. These experiments were designed to determine
whether intra-mPFC DHPG produced a sensitized motor response in cocaine-sensitized
rats relative to saline controls. Data from these experiments was also used to rule out the
possibility that a single dose of DHPG induces heightened motor activity. In these
experiments, rats were treated with systemic cocaine (15 mg/kg, i.p.) or saline for 4
consecutive days. Following 7 or 21 days post-cocaine exposure, DHPG was infused into
the mPFC and motor activity was monitored for 120 min.
VTA Experiments
These experiments measured the effects of VTA AMPA receptor antagonism on
intra-mPFC DHPG-induced cross-sensitization to cocaine. The AMPA receptor
antagonist CNQX (1 nmol/side) or saline was microinjected into the VTA 5 min prior to
microinjections of DHPG or saline into the mPFC for four consecutive days. A challenge
injection of cocaine was administered 7 days following the final microinjection and
motor activity was monitored for 120 min.
Sensitization Experiments
Initiation. This set of experiments measured the effects of mGluR5 antagonism on
the initiation of cocaine sensitization. On the first day of initiation experiments, animals
were placed in the activity chambers for 60 min before either mGluR5 antagonist MTEP
(15 nmol/side) or saline was microinjected into the mPFC five minutes prior to an i.p.
injection of saline. Locomotor activity was then monitored for 120 min and these data
were later analyzed for the purpose of determining any nonspecific effects of the
antagonists. On the second day of initiation experiments, animals were placed in activity
chambers for 60 min and then received an mPFC microinjection of either MTEP or saline
that preceded by 5 min a systemic injection of saline or cocaine (15 mg/kg, i.p.).
Locomotor activity was then recorded for 120 min. On the 3rd-5th days of these
experiments, animals received the same treatment they received on the second day and
were immediately placed back in their home cages following injections. Motor activity in
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response to a challenge injection of saline or cocaine was measured six or seven days
following the final microinjection, respectively.
Expression. This set of experiments measured the effects of mGluR5 antagonism
on the expression of cocaine sensitization at 7 and 21 of abstinence. Animals were given
cocaine (15 mg/kg, i.p.) or saline injections for 4 consecutive days. Seven or 21 days
following the last of the daily cocaine injections, mGluR5 antagonist MTEP (15
nmol/side) or saline was microinjected into the mPFC five min prior to a challenge
injection of cocaine (15 mg/kg, i.p.), and motor activity was monitored for 120 min. A
day prior to the cocaine challenge, animals received an mPFC microinjection of either
saline or MTEP (15 nmol/side) 5 min prior to a systemic injection of saline and
locomotor activity was monitored for 120 min.
Results
Group I mGluR Stimulation in the mPFC Induces Cross-Sensitization to Cocaine
Animals that had received once daily mPFC microinjections of the Group 1
mGluR agonist DHPG over 4 consecutive days were significantly more active in
response to cocaine 1 week later than were their saline counterparts (Treatment F
(1,14)=6.425, p=0.0238; Time F(7, 98)=25.54, p<0.0001; Interaction F(7, 98)=3.213,
p=0.0042), as evidenced through the monitoring of motor activity (photocell counts) in
response to a challenge injection of cocaine (15 mg/kg, i.p.) over a 120 min period
(Figure 1).The mean cocaine-induced activity level measured from DHPG-pretreated
animals was comparable to that from cocaine-sensitized animals, suggesting that Group I
mGluR stimulation in the mPFC results in cross-sensitization to cocaine.
Cross-Sensitization Is Mediated by mGluR5
In replication of the experiments above, repeated injections of DHPG into the
mPFC induced cross-sensitization to cocaine (Figure 2). Co-administration of DHPG and
the mGluR5 antagonist MTEP inhibited cross-sensitization (Treatment F(3,26)=3.518,
p=0.0290; Time F(7,182)= 51.67, p<0.0001; Interaction F(21,182)=2.734, p=0.0002;
Figure 2a). By contrast, co-administration of DHPG with mGluR1 antagonist
YM298198 did not inhibit cross sensitization (Figure 2b). Taken together, these findings
suggest the observed DHPG-induced cross-sensitization is mediated by mGluR5. Note:
The average locomotor activity of the MTEP group was not significantly different from
the DHPG group during the first time point due to the high activity level of one animal.
The removal of this animal’s data from the analysis reveals significant difference
between these two groups, however, the absence of infection or inaccurate injector
placement in the animal precluded its elimination.
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Figure 1. Locomotor Response to a Challenge Injection of Cocaine. Locomotor
response (photocell counts) to a challenge injection of cocaine (15 mg/kg, i.p.) is shown
over a 120 min time period. Animals received mPFC microinjections of DHPG (15
nmol/side) (n=8) or saline (n=8) for 4 consecutive days 7 days prior to the cocaine
challenge. *p< 0.05 compared to saline.
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Figure 2. DHPG-Induced Cross-Sensitization Is Mediated by mGluR5. a) Locomotor
response to a challenge injection of cocaine is shown over a 120 min time period.
Animals received mPFC microinjections of DHPG+MTEP (15 nmol/side) (n=8), DHPG
(15 nmol/side) (n=8), MTEP (15 nmol/side)(n=8), or saline (n=8) for 4 consecutive days
one week prior to the cocaine challenge. *p< 0.05 compared to saline. +p< 0.05 compared
to DHPG.b) Locomotor response to a challenge injection of cocaine is shown over a 120
min time period. Animals received mPFC microinjections of DHPG+YM198298 (15
nmol/side) (n=8), DHPG (15 nmol/side) (n=8), YM198298 (15 nmol/side) (n=8), or
saline (n=8) for 4 consecutive days one week prior to the cocaine challenge. *p< 0.05
compared to saline.
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VTA AMPA Receptor Blockade Inhibits DHPG-Induced Cross-Sensitization
Group I mGluR activation within the mPFC may be important for recruiting the
VTA, which is critical for sensitization (Kalivas, 2001). Thus, the AMPA receptor
antagonist CNQX or saline was microinjected into the VTA 5 min prior to intra-mPFC
DHPG or saline to test whether DHPG-induced cross-sensitization relied on activation of
the VTA (Figure 3). In agreement with this idea, intra-VTA CNQX blocked crosssensitization induced by intra-mPFC DHPG, AMPA receptor activation in the VTA is
necessary for mPFC DHPG-mediated cross-sensitization (Treatment F(3, 21)=5.607,
p=0.0005; Time F(7, 147)=73.85, p<0.0001; Interaction F(21, 147)=4.460, p<0.0001)
(Figure 3).
mPFC mGluR5 Blockade and Cocaine Sensitization
Given that mPFC mGluR5 inhibition was sufficient to prevent the DHPG-induced
cross-sensitization, it was important to test whether the initiation and/or expression of
cocaine sensitization similarly relied on mGluR5 in the mPFC. mGluR5 inhibition via
mPFC microinjections of MTEP was not sufficient to prevent the initiation of cocaine
sensitization . Motor activity in response to a challenge injection of cocaine did not
significantly differ between animals that had received saline or MTEP prior to their
sensitizing cocaine injections; all animals that had received repeated cocaine exhibited a
sensitized response to the cocaine challenge, indicating that mGluR5 blockade in the
mPFC is not sufficient to prevent the establishment of cocaine sensitization (Figure 4).
mGluR5 in the mPFC appears necessary for late, but not early, expression of
sensitization. Animals received repeated i.p. injections of saline or cocaine (15 mg/kg) 7
(Figure 5a) or 21 days (Figure 5b) prior to the cocaine challenge. Animals received an
mPFC microinjection of either saline or mGluR5 antagonist MTEP 5 min prior to the
cocaine challenge. Animals that had received repeated cocaine exhibited a sensitized
response to the challenge regardless of whether they received an mPFC microinjection of
saline or MTEP at 7 days (Treatment F(3, 23)=2.408, p=0.0931; Time F(7, 161)=107.5,
p<0.0001; Interaction F(21, 161)=6.121, p<0.0001) (a), while only animals that received
repeated cocaine and a saline microinjection before the cocaine challenge exhibited a
sensitized response at 21 days (Treatment F(3, 25)=3.515, p=0.0297; Time F(7.
175)=82.25, p<0.0001; Interaction F(21, 175)=6.195, p<0.0001) (b). Our results suggest
mGluR5 antagonism in the mPFC is sufficient to prevent the expression of sensitization
at 21, but not 7 days from the last cocaine injection, suggesting mGluR5 activity in the
mPFC plays a role in the expression of late sensitization, but is not involved in early
expression.
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Figure 3. VTA AMPAR Blockade Prevents DHPG-Induced Cross-Sensitization.
Locomotor response to a challenge injection of cocaine in shown over a 120 min time
period. Animals received four consecutive daily intra-VTA microinjections of saline or
CNQX (1 nmol/side) followed by an intra-mPFC microinjection of saline or DHPG (15
nmol/side) five minutes later. *p< 0.05 compared to saline. +p< 0.05 compared to DHPG.
Saline/saline: n=6; saline/CNQX: n=6; saline/DHPG: n=6; DHPG/CNQX: n=7.
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Figure 4. Effect of mPFC mGluR5 Blockade on the Initiation of Sensitization.
Locomotor response to a challenge injection of cocaine is shown over a 120 min time
period. Animals received an mPFC microinjection of MTEP (15 nmol/side) or saline 5
min prior to systemic cocaine or saline for 4 consecutive days one week prior to the
cocaine challenge (n=8 for all groups). *p< 0.05 compared to saline.

23

a

Photocell Count

5000

*

Saline/Saline
Saline/MTEP
Cocaine/Saline
Cocaine/MTEP

*

4000
3000

*

2000
1000
0

30

60

90

120

Time (min)

b

Photocell Count

4000
3000
2000

*

Saline/Saline
Saline/MTEP
Cocaine/Saline
Cocaine/MTEP

*

+
+

1000
0

30

60

90

120

Time (min)

Figure 5. Effect of mPFC mGluR5 Blockade on the Expression of Sensitization.
Locomotor response to a challenge injection of cocaine (15 mg/kg, i.p.) is shown over a
120 min time period. Animals received systemic injections of cocaine (15 mg/kg, i.p.) or
saline for four consecutive days 7 (a) or 21 (b) days prior to the cocaine challenge. On the
day of the challenge, animals received an mPFC microinjection of MTEP (15 nmol/side)
or saline five minutes prior to cocaine (15 mg/kg, i.p.). *p< 0.05 compared to
saline/saline. +p<0.05 compared to cocaine/saline. Saline/saline: n=9; saline/cocaine:
n=10; MTEP/saline: n=7; MTEP/cocaine: n=9.
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mGluR5 Activation Alone Does Not Produce a Sensitized Response in Sensitized
Animals
Given that intra-mPFC administration of DHPG induced cross-sensitization to
cocaine, we tested whether DHPG could elicit a sensitized response in cocaine-sensitized
rats. Locomotor activity in response to a challenge mPFC DHPG microinjection did not
differ between saline- and cocaine-treated rats at 7 or 21 days following the last cocaine
exposure (data not shown). Based on this data, it appears that mGluR5 activation in the
mPFC is not sufficient to elicit a sensitized behavioral response in animals sensitized to
cocaine.
Histology
Histological analysis was performed on the brains of all animals in the study, as
described in the methods. Injector sites of animals included in the analysis were located
in the prelimbic (Cg3 area) or infralimbic regions of the prefrontal cortex (Figure 6a, c).
The majority of injector placements were +3.20 mm from Bregma. Injector locations for
animals included in the VTA experiments were in the VTA, at -5.2 and -5.3 mm from
Bregma (Figure 6b, d). Within each experimental group, several animals were
eliminated from analysis due to infection or incorrect cannulae placement (n=24 total).
Discussion
The present studies demonstrate that repeated mGluR5 activation in the mPFC
induces a cross-sensitization to cocaine that can be prevented through AMPA receptor
blockade in the VTA, suggesting glutamatergic transmission from the mPFC to the VTA
is necessary for this cross-sensitization to occur. Furthermore, mPFC mGluR5 blockade
prevents the expression of late, but not early, cocaine sensitization, which may indicate
that modifications in mPFC mGluR5 represent one lasting neuroadaptation that results
from repeated cocaine exposure.
We found that repeated local activation of group I mGluRs in the mPFC lead to
cross-sensitization to cocaine in naïve rats. Further investigation showed that mGluR5,
rather than mGluR1, was responsible for this effect and VTA AMPA receptor
antagonism prevented it. Our results suggest glutamatergic input from mPFC pyramidal
neurons to the VTA mediated the cross-sensitization we observed in response to repeated
intra-mPFC DHPG. Glutamate in the VTA is known to be necessary for the initiation of
sensitization (Kalivas and Alesdatter, 1993). In addition, sensitization is associated with
enhanced glutamate release in the VTA and insertion of AMPA receptors lacking the
GluR2 subunit (Fitzgerald et al., 1996; Kalivas and Duffy, 1998). Furthermore, repeated
AMPA injections into the VTA (Dunn et al., 2005) have been shown to induce crosssensitization to cocaine. Similarly, as was shown in the present report, repeated mPFC
mGluR5 stimulation and subsequent glutamate release in the VTA may have activated
AMPA receptors on VTA dopaminergic output neurons, resulting in dopamine
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Figure 6. Microinjection Placement in the mPFC and the VTA. Representative
photomicrographs and stereotaxic atlas schematics of injection sites in the mPFC (a, c)
and VTA (b, d). Top panels show injector placement in cresyl violet-stained coronal
sections from representative brains. Bottom panels show illustrations of injector
placement from all animals included in the analysis. Illustrations were derived from ‘The
Rat Brain in Stereotaxic Coordinates’ (Paxinos and Watson, 1997). fmi=forceps minor of
the corpus callosum; PBP=parabrachial pigmented nucleus; SNr=substantia nigra
reticulata; PN=paranigral nucleus Cg3=cingulate cortex, area 3; IL=infralimbic cortex.
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release in the nucleus accumbens (Giorgetti et al., 2001), a critical event common to
virtually all drugs of abuse (Kuhar, 1991). Therefore, repeated mPFC DHPG
administration may mimic some key processes that occur in response to repeated cocaine
exposure and lead to sensitization, however, the mechanisms that fuel these processes
may differ, as discussed below.
One surprising aspect of our results is that while mGluR5 activation in the mPFC
via DHPG is sufficient to induce sensitization, these receptors are not necessary for the
initiation of sensitization to cocaine, as evidenced by the failure of the mGluR5
antagonist MTEP to prevent initiation of cocaine-induced sensitization. One possible
explanation for this is that while mGluR5 activation of pyramidal projection neurons to
the VTA can induce sensitization, cocaine is capable of activating VTA dopaminergic
cells independent of mPFC involvement. Indeed, intra-VTA cocaine administration has
been shown to induce sensitization, as has the intra-VTA administration of the dopamine
re-uptake inhibitor GBR 12909 (Cornish and Kalivas, 2001; Steketee, 1998). Through
dopamine transporter blockade, cocaine increases dopamine levels in the VTA. This
elevation in dopamine leads to glutamate release via activation of dopamine D1 receptors
that consequently activates dopaminergic output neurons in the VTA (Cornish and
Kalivas, 2001; Kalivas and Duffy, 1998). Furthermore, the systemic administration of
cocaine may result in the activation of mPFC pyramidal neurons in ways that do not
involve, or at least are not limited to, the stimulation of mGluR5. Thus, selective mGluR5
blockade in the mPFC may not be sufficient to block initiation because dopaminergic
projection neurons in the VTA are receiving glutamatergic input through means
independent of mGluR5 activation in the mPFC.
In contrast to the initiation experiments, our expression studies revealed that
mGlur5 in the mPFC is necessary for the long-term expression of cocaine sensitization,
but its stimulation alone is not sufficient to elicit a sensitized locomotor response in
cocaine-sensitized animals.
Our results show that mGluR5 blockade in the mPFC did not prevent the
expression of sensitization at 7 days following repeated cocaine exposure, but did prevent
it at 21 days. This may have occurred because cocaine-evoked mPFC glutamate levels are
elevated during early sensitization (measured at 7-days after daily cocaine treatment) but
return to baseline by late sensitization (30-days post cocaine exposure) (Williams and
Steketee, 2004). mGluR5 blockade during early sensitization may not have been
sufficient to decrease the excitability of mPFC pyramidal neurons because, in the
presence of cocaine, there was enough glutamate available to stimulate AMPA receptors.
However, when cocaine-induced glutamate levels normalize during late sensitization,
mGluR5 may have a greater influence over neuronal excitability and its blockade at this
point may reduce firing to a degree that prevents expression. A related possibility is that
other cocaine-induced neurotransmitter and/or receptor changes that occur in the mPFC
during late sensitization depend on mGluR5 function and mGluR5 antagonism at this
stage could affect expression. This possibility is discussed in greater detail below. A third
reason why mGluR5 blockade may have prevented late but not early expression is that
the elevations in cocaine-induced glutamate levels during early sensitization may have
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lead to increased activation of the peri-synaptically located mGluR5 and subsequent
changes in receptor number, function, or downstream signaling that effectively altered
mGluR5 regulation over neuronal firing in the mPFC. Such cellular modifications may
not have been in place until late sensitization.
While blockade of mGluR5 could prevent the expression of late sensitization,
stimulation of these receptors with DHPG failed to produce a sensitized locomotor
response in animals previously sensitized to cocaine. This result suggests that stimulation
of mPFC mGluR5 is not sufficient to produce a locomotor response. While mGluR5 may
result in activation of VTA neurons and dopamine release in the NAc, locomotor activity
likely requires a greater level of dopamine that may only be achievable through the
dopamine transporter blockade produced by cocaine.
Some evidence indicates that mGluR5s, including those in the mPFC, may
contribute to cocaine sensitization. Most importantly, mGluR5-null mice do not sensitize
to or self-administer cocaine (Chiamulera et al., 2001). Additionally, mGluR5 stimulation
results in an increase in mPFC neuronal excitability (Bandrowski et al., 2003; Marek and
Zhang, 2008). The goal of the experiments delineated in this report was to uncover a
possible role for mPFC mGluR5 in cocaine sensitization that could eventually shed more
light on the mechanisms underlying the increased excitability of mPFC pyramidal
neurons following repeated cocaine exposure. Support for an increase in intrinsic mPFC
neuronal excitability comes from evidence demonstrating an increase in L-type calcium
channel current (Nasif et al., 2005) and number (Ford et al., 2009) following repeated
cocaine administration.
A decrease in inhibitory tone is suggested by studies showing a reduction in
mPFC Group II mGluR (Xie and Steketee, 2008), D2 (Beyer and Steketee, 2002; Liu and
Steketee, 2011) and GABAB (Steketee and Beyer, 2005) receptor function following
repeated cocaine exposure (Bowers et al., 2004). An increase in excitatory drive may
result from the elevation in mPFC dopamine levels that occurs during late sensitization
(Williams and Steketee, 2005). Evidence suggests mPFC pyramidal neurons fluctuate
between states of high and low excitability and dopamine D1 and D2 receptors play
opposing roles in the regulation of these states. D1 receptor activation is believed to
increase and then maintain the high excitability state while D2 receptor stimulation is
thought to convert pyramidal cells from the high to the low excitability state (Seamans
and Yang, 2004; Steketee, 2005). The combination of the reduction in dopamine D2
receptor function and increase in intrinsic neuronal excitability may pave the way for
increased dopamine D1 tone and the consequent perpetuation of a high-excitability state
in mPFC pyramidal projection neurons. It has been suggested that mGluR5 is essential
for maintaining neuronal firing in the mPFC (Homayoun and Moghaddam, 2010). The
prevention of late-stage expression shown in the present study raises the question of
whether the regulatory role of mPFC mGluR5 serves to perpetuate the high-activity state
that could result from loss of D2 receptor function following repeated cocaine exposure
(Beyer and Steketee, 2002; Bowers et al., 2004). In this scenario, no drug-induced
alterations would necessarily have to take place in mGluR5, however, its activation
would nevertheless be critical for late expression. Acute mPFC mGluR5 blockade
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immediately prior to cocaine exposure during late sensitization would prevent or
attenuate the glutamatergic transmission to the NAc required for expression. Further
studies should address whether repeated cocaine leads to changes in mPFC mGluR5
function or coupling, or if mGluR5 simply holds greater influence over pyramidal cell
firing due to changes in other receptors or neurotransmitters following sensitization.
A caveat of the present study is the possibility that intra-mPFC-administered
drugs activated off-target receptors and the consequent stimulation of these receptors was
partially responsible for the effects we observed. While DHPG has proved to be highly
selective for Group I mGluRs, it has been shown that it can interact with NMDA
receptors under certain conditions (Wisniewski and Car, 2002)). mGluR5 antagonist
MTEP is preceded by 2-methyl-6-(phenylethynyl) pyridine hydrochloride (MPEP). In
addition to being a selective, noncompetitive mGluR5 antagonist, evidence suggests
MPEP acts on mGluR1d and NMDA receptors (Lea and Faden, 2006). By contrast,
MTEP has far less potential for off-target effects and is considered the most selective and
least problematic of all mGluR5 antagonists (Lea and Faden, 2006)). YM298198 is a
potent mGluR1 antagonist with very few off-target effects (Fukunaga et al., 2007). While
we recognize the possibility of an unintended site playing a role in our results, our failure
to observe DHPG-induced cross-sensitization in animals that additionally received
mGluR5 antagonist MTEP suggests mGluR5 in the mPFC was primarily responsible for
our findings. AMPA receptor antagonist CNQX also acts as a weak antagonist at the
glycine site of NMDA receptors, however, since our goal was to suppress mPFCmediated glutamatergic input to VTA dopaminergic projection neurons, this action would
not compromise the integrity of our findings. Finally, the lack of significant difference in
cocaine-induced locomotion between animals that received saline and those that received
the drug alone (e.g. mPFC saline vs. mPFC YM298198) suggests the drugs we employed
did not induce any measurable changes in behavior.
In conclusion, the experiments delineated in this paper show that mGluR5
activation in the mPFC can induce a cross-sensitization to cocaine that can be prevented
through the blockade of AMPA receptors in the VTA. Furthermore, our studies show that
mGluR5 inhibition in the mPFC prevents the expression of late, but not early, behavioral
sensitization to cocaine. The suggested involvement of mGluR5 in late-stage sensitization
is particularly important because the cocaine-induced changes that may be occurring in
this receptor could potentially contribute to the persistence of drug-seeking behavior and
propensity for relapse, especially since these alterations are taking place in the PFC.
Taken together, the data demonstrate that mPFC mGluR5s are sufficient, but not
necessary for the initiation of cocaine sensitization and necessary, but not sufficient for
the expression of cocaine sensitization. These results suggest a possible role for mPFC
mGluR5 in the maintenance of the sensitized state, and its associated drug-seeking
behavior.

29

Chapter 3. Metabotropic Glutamate Receptor 5 in the Medial Prefrontal Cortex:
Role in Mesocorticolimbic Glutamate Release in Cocaine Sensitization
Introduction
Glutamatergic input from the medial prefrontal cortex (mPFC) to the ventral
tegmental area (VTA) and the nucleus accumbens (NAc) is necessary for the initiation
and expression, respectively, of the behavioral sensitization to cocaine (Pierce et al.,
1998; Steketee, 2003)). It has been demonstrated that mPFC pyramidal projection
neurons become hyperexcitable following repeated cocaine exposure (Nasif et al., 2005)
(Ford et al., 2009) (Hu, 2007), an event that would ultimately result in increased
glutamatergic input to the VTA and the NAc. Imaging studies in human addicts have
shown a similar increase in mPFC activity in response to cocaine and related cues as well
as a decrease in responsivity to non-drug stimuli (Goldstein and Volkow, 2011). This
heightened neuronal attentiveness to cocaine and its cues at the expense of non-drug
stimuli may play a significant role in the exceedingly high relapse rate of cocaine addicts.
Thus, a comprehensive understanding of the regulation of mPFC cell excitability in the
addicted brain could potentially lead to effective pharmacotherapies to reduce the risk of
relapse.
Metabotropic glutamate receptor 5 (mGluR5), a Gq/G11-coupled Group I
receptor abundant in corticolimbic regions, has been shown to influence neuronal
excitability (Homayoun and Moghaddam, 2010; Kew and Kemp, 2005). mGluR5
stimulation in mPFC, hippocampal, and nigral slices results in excitatory postsynaptic
potentials (EPSPs), depolarization, and increased firing frequency (Marek and Zhang,
2008) (Fitzjohn et al., 1999; Homayoun and Moghaddam, 2010; Marino et al., 2001). By
contrast, mGluR5 blockade in the mPFC reduced firing frequency by about fifty percent
(Homayoun and Moghaddam, 2006). Moreover, the firing rate of neurons with the
highest baseline firing rate was reduced following antagonist administration to a greater
extent than that of neurons with a lower pre-antagonist firing rate (Homayoun and
Moghaddam, 2006; Homayoun and Moghaddam, 2010) possibly suggesting mGluR5
activity can substantially influence the total output of the mPFC. In recent years, studies
have implicated mGluR5 in cocaine addiction. mGluR5-null mice do not sensitize to
cocaine (Chiamulera et al., 2001) and systemic administration of mGluR5 antagonists
prevents sensitization and reinstatement (Martin-Fardon and Weiss, 2012; Platt et al.,
2008). Selective manipulation of mGluR5 in reward-processing brain regions has also
affected addiction-related behaviors. mGluR5 blockade in the NAc prevented drugseeking behavior, while mGluR5 stimulation enhanced it (Wang et al., 2012). In the
mPFC, repeated mGluR5 activation induced cross-sensitization to cocaine, while
mGluR5 antagonism attenuated cocaine-induced locomotor activity in sensitized rats
during late expression (Timmer and Steketee, 2012). Impaired cue-induced reinstatement
was demonstrated following the selective knock-down of mGluR5 in dopamine D1
receptor-expressing neurons, suggesting mGluR5 is important in the formulation of
associations between cocaine and previously unrelated stimuli (Novak et al., 2010).

30

Taken together, the abovementioned evidence suggests mGluR5 activation in the
mPFC may influence pyramidal cell output and consequently alter glutamatergic input to
the VTA and NAc. The present study examined the effects of mPFC mGluR5 activation
on glutamate levels in the mPFC, VTA, and NAc during early and late sensitization.
Materials and Methods
Animals and Surgery
All animal procedures were carried out in accordance with the National Institutes
for Health Guide for the Care and Use of Laboratory Animals and all experiments were
approved by the University of Tennessee Health Science Center Animal Resources
Advisory Committee. Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing
275-300 g at the time of surgery were housed under a 12-hour light/dark cycle and
provided ad libitum access to food and water. Animals were anesthetized with a ketamine
hydrochloride (80 mg/kg, i.p.) and xylazine (6 mg/kg, i.p.) cocktail and placed in a
stereotaxic instrument (Kopf Instruments). Microdialysis cannulae (20 gauge, 14 mm,
stainless steel) were unilaterally placed 3 mm above the mPFC (A/P +3.2, and M/L +.6
mm from bregma; -1.5 mm from dura) and either the VTA (A/P -4.8 mm and M/L +.6
mm from bregma; -5.4 mm from dura) or NAc (A/P -1.4 mm and M/L +1.4 mm from
bregma; -5.0 mm from dura). Obturators (14 mm, 25 gauge, stainless steel) were inserted
in the cannulae to prevent occlusion. Animals were given at least seven days for recovery
prior to the commencement of experiments.
Cocaine Pretreatment
Intraperitoneal injections of either cocaine (15 mg/kg) or saline (1 mL/kg) were
administered in the animals’ home cages for four consecutive days, with the fourth
injection day preceding the microdialysis experiment by one, seven, or twenty-one days.
Distinct groups of animals were used for each condition.
In Vivo Microdialysis
Microdialysis probes (2 mm active membrane) were inserted into the cannulae
and dialysis buffer (2.7 mM KCl, 140 mM NaCl , 1.2 mM CaCl, 1.2 mM MgCl; pH: 7.4
with phosphate-buffered saline) began infusing three hours prior to the start of sample
collection. Samples were collected every 20 minutes in microcentrifuge tubes containing
10 uL of 0.05 mM HCL. Four initial baseline samples were collected prior to Group I
mGluR agonist DHPG (dihydroxyphenylglycine; TOCRIS) infusion through the dialysis
probe. Three concentration (0.5 mM, 5 mM, 50 mM) of DHPG were infused in an
increasing manner and four samples were collected during each concentration. Following
collection, samples were stored at -80°C prior to analysis.
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High Performance Liquid Chromatography
Sample glutamate levels were analyzed using a fluorescence spectrophotometer
system as previously described (Xie and Steketee 2008). Samples were derivatized (20
uL sample+20 uL fluoraldehyde) and 25 uL of the mixture was injected onto a reversedphase column. The mobile phase (62 mM NaH2PO4, 0.5% v/v tetrahydrofuran, 40% v/v
methanol; pH=6.3 with 6 N NaOH) flowed at a rate of 1 mL/min. Glutamate was
detected at an excitation wavelength of 260 nm and an emission wavelength of 455 nm.
An external standard curve ranging from 0.5-25 pmol served as a basis for glutamate
concentration derivation.
Locomotor Activity Analysis
Cocaine-induced locomotor activity was measured in all animals between 1 and 3
days following experiments to ensure pretreatment effectiveness. Animals were placed in
activity chambers (45 x 24 x 19 cm) for 60 min prior to cocaine administration (15
mg/kg, i.p.) to allow for adaptation, and then locomotor activity was monitored for 120
min following injection.
Histology
Subsequent to experiment completion, animals were deeply anesthetized with
sodium pentothal (333 mg/kg) and intracardially perfused with phosphate-buffered saline
(50 mL) followed by 4% formaldehyde. Brains were removed from the skull cavity and
allowed to sit in a formaldehyde-filled vial for at least a week prior to sectioning. Coronal
slices (100 um) were cut using a vibratome, mounted on gelatin-coated slides, and stained
with cresyl violet. Probe placement was verified using light microscopy and a rat brain
atlas (Paxinos and Watson 1997) and data from animals with incorrect probe placements
were excluded from analysis
Statistics
Microdialysis data were converted to percentage-of-baseline values prior to
analysis. The baseline for each data set was acquired by averaging the 3 most consistent
values of the 4 initial baseline samples. Microdialysis data were analyzed using a twoway repeated measures analysis of variance (ANOVA) followed by a modified least
significances (LSD) test (Milliken and Johnson 1984), if necessary. Behavioral data were
analyzed using an unpaired t-test.
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Drugs
DHPG was purchased from Tocris Bioscience (Ellisville, MO, USA) and cocaine
hydrochloride was purchased from Sigma Chemical Company (St. Louis, MO, USA). All
drugs were diluted in saline (0.9% sodium chloride).
Results
Behavior
Figure 7 shows motor activity recorded in response to a challenge injection of
cocaine administered within 72 hours following microdialysis experiments for saline- and
cocaine-pretreated rats. Data from all three time points were pooled and analyzed using
an unpaired t-test. Cocaine-pretreated rats were significantly more active in response to
the cocaine challenge than saline-pretreated controls (t=7.755, p<0.0001), suggesting that
repeated cocaine induced sensitization.
In vivo microdialysis
Figure 8 illustrates the effects of intra-mPFC DHPG infusion (0.5, 5 and 50 uM)
on mPFC glutamate levels in sensitized and non-sensitized rats at 1, 7, and 21 days
following the last injection of cocaine or saline. The data were initially analyzed using a
two-way repeated measures ANOVA. When an interaction effect was observed, further
analysis using a modified least significant differences (LSD) test (Milliken and Johnson
1984) was carried out to determine the time point(s) at which the difference occurred.
Intra-mPFC DHPG administration increased mPFC glutamate levels at 7 days
post-injection in rats that had previously received repeated cocaine but not saline (Figure
8a) (Interaction:F(14, 364)=2.64, p=0.0010; Treatment: F(1, 364)=8.440, p=0.0074;
Time: F (14, 364)=1.977, p=0.0186). No significant differences in extracellular mPFC
glutamate levels were observed between two groups at 1 (Figure 8b) or 21 (Figure 8c)
days post-injection, however, an interaction effect approached significance at 1 day
withdrawal (1 Day: Interaction: F(14, 336)=1.703, p=0.0534; Treatment: F(1,
336)=4.948, p=0.0358; Time: F(14, 336)=2.161, p=0.009) (21-Days: Interaction: F(14,
322)=1.424, p=0.1399; Treatment: F(1,322)=0.02453, p=0.8769; Time: F(14,
322)=1.978, p=0.0189)Baseline glutamate levels between cocaine- and saline-pretreated
rats did not differ significantly at any of the three time points.
Figure 9 shows the effects of intra-mPFC DHPG administration (0.5, 5 and 50
uM) on glutamate levels in the NAC in cocaine- and saline-pretreated rats at 1, 7 and 21
days post-injection. Data were analyzed using a two-way repeated measures ANOVA
followed by a LSD test when appropriate.
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Figure 7. Effect of Repeated Cocaine Exposure on Cocaine-Induced Locomotion.
Locomotor behavior (photocell counts) in response to a challenge injection of cocaine is
shown for sensitized animals and saline controls. *=p<0.05
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Figure 8. Effect of Intra-mPFC mGluR5 Activation on mPFC Glutamate Levels.
mPFC glutamate levels (shown as % of baseline) are displayed over 240 min for cocainesensitized and control animals in response to 3 concentrations of DHPG (0.5, 5, 50 uM)
at 1(a), 7(b), and 21(c) days withdrawal. *=p<0.05 between saline and cocaine animals.
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Figure 9. Effect of Intra-mPFC mGluR5 Activation on NAc Glutamate Levels. NAc
glutamate levels (shown as % of baseline) are displayed over 240 min for cocainesensitized and control animals in response to 3 concentrations of DHPG (0.5, 5, 50 uM)
at 1(a), 7(b), and 21(c) days withdrawal. *=p<0.05 between saline and cocaine animals.
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When infused into the mPFC, DHPG significantly increased NAC glutamate
levels in cocaine-pretreated rats at 21 days post-injection (Figure 9c) (Interaction: F(14,
140)=1.963, p=0.0249; Treatment: F(1, 140)=7.373, p=0.0217; Time: F(14, 140)=1.431,
p=0.1461). NAC glutamate levels did not differ between cocaine- and saline-pretreated
rats at 1 (Figure 9a) or 7 (Figure 9b) days post-injection (1 Day: Interaction: F(14,
168)=0.4758, p=0.9435; Treatment: F(1, 168)=0.04225, p=0.8406; Time: F(14,
168)=0.9407, p=0.5167) (7 Days: Interaction: F(14, 154)=1.233, p=0.2566; Treatment:
F(1, 154)=2.150, p=0.1706; Time: F(14, 154)=1.018, p=0.4386). There were no
significant differences in baseline glutamate levels between the two groups at any of the
three time points.
Figure 10 depicts VTA glutamate levels following intra-mPFC DHPG infusion
(0.5, 5 and 50 uM) in cocaine- and saline-pretreated rats at 1 (Figure 10a), 7 (Figure
10b) and 21 (Figure 10c) days post-injection. The data was analyzed using a two-way
repeated measures ANOVA.
Intra-mPFC DHPG administration did not differentially affect VTA glutamate
levels in saline- and cocaine-pretreated rats at 1, 7 or 21 days post-injection, however, a
trend towards increased glutamate levels in cocaine-pretreated rats was observed at 7
days post-injection (Figure 10b) (1 Day: Interaction: F(14, 140)=0.8216, p=0.6447;
Treatment: F(1, 140)=0.0042, p=0.9491; Time: F(14, 140)=1.071, p=0.3888) (7 Days:
Interaction: F(14, 168)=1.084, p=0.3755; Treatment: F(1, 168)=5.729, p=0.0339; Time:
F(14, 168)=0.7618, p=0.07090) (21 Days: Interaction: F(14, 154)=0.8385, p=0.6266;
Treatment: F(1, 154)=0.7894, p=0.3933; Time: F(14, 154)=1.032, p=0.4245). Baseline
glutamate levels did not differ significantly between the two groups at any of the three
time points.
Histology
Photomicrographs of typical microdialysis probe tracks in the mPFC, NAc and
VTA are shown in Figure 11. In the mPFC, dialysis probes were located in the Cg3 or
infralimbic regions (Figure 11a). Dialysis probes in the NAc were medial to the anterior
commissure (ac) and within the core or shell of the NAc (Figure 11b). In the VTA,
microdialysis probes were medial to the substantia nigra (SnC, SnR) and adjacent to the
paranigral nucleus (PN) and parabrachial pigmented nucleus (PBP) (Figure 11c).
Discussion
The effects of mPFC mGluR5 activation on mPFC, VTA and NAc glutamate
levels in sensitized and non-sensitized animals were explored in the present study. We
did not observe an effect of intra-mPFC mGluR5 activation on glutamate levels in any
brain region at any time point in control animals. However, our data show that mPFC
mGluR5 stimulation increases glutamate levels within the mPFC at 7 days, but not 1 or
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Figure 10. Effect of Intra-mPFC mGluR5 Activation on VTA Glutamate Levels.
VTA glutamate levels (shown as % of baseline) are displayed over 240 min for cocainesensitized and control animals in response to 3 concentrations of DHPG (0.5, 5, 50 uM)
at 1(a), 7(b), and 21(c) days withdrawal.
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Figure 11. Microdialysis Probe Placement in the mPFC, NAc, and VTA.
Representative photomicrographs of microdialysis probe sites in the mPFC (a), Nac (b),
and VTA (c). fmi=forcepts minor corpus callosum, ac=anterior commissure,
PBP=parabrachial pigmented nuclei, PN=paranigral nuclei, SnC=substantia nigra
compacta, SnR=substantia nigra reticulata.
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21 days, withdrawal in sensitized rats. In the NAc, intra-mPFC mGluR5 activation leads
to elevated glutamate levels at 21, but not 7 or 1, days post-injection in sensitized
animals. mPFC mGluR5 stimulation did not significantly alter glutamate levels in the
VTA at any time point, however, a subset of animals exhibited an increase in glutamate
levels at 7 days withdrawal. These results imply repeated cocaine exposure leads to a
transient mPFC mGluR5-mediated glutamate increase in the mPFC and a delayed, but
possibly lasting, mPFC mGluR5-induced increase in NAc glutamate levels.
mPFC mGluR5 and mPFC Glutamate
The present data show that intra-mPFC mGluR5 activation increases mPFC
glutamate levels at 7, but not 1 or 21, days following the last sensitizing cocaine
injection. This suggests repeated cocaine exposure may transiently alter mGluR5 activity
in a manner that yields mPFC-specific glutamate increases, or induce temporary
mGluR5-independent neuronal changes that result in heightened glutamate release
following mGluR5 stimulation. mGluR5 is generally located postsynaptically and serves
to increase the excitability of mPFC pyramidal neurons (Homayoun and Moghaddam,
2010; Kew and Kemp, 2005).
Given that the mPFC contains projections that terminate in various brain regions
(Hoover and Vertes, 2007; Sesack et al., 1989), including the mPFC, one possibility is
that sensitization-induced changes occur earlier in mGluR5-bearing mPFC-projecting
neurons than in mGluR5-containing neurons that project to other brain areas, such as the
NAc. As discussed in the following section, we observed elevated NAc glutamate levels
at 21 days withdrawal in sensitized rats in response to mPFC mGluR5 stimulation,
suggesting mPFC mGluR5 increases neuronal firing during late sensitization. It is
conceivable that early glutamate release via local mPFC neurons play a role in facilitating
later adaptations in NAc projections. A previous study demonstrated increased cocaineinduced mPFC glutamate in sensitized animals at 7, but not 30, days withdrawal
(Williams and Steketee, 2004), suggesting transient mPFC glutamate alterations occur
during early sensitization. mGluR5 activation in a select group of local mPFC projection
neurons may contribute to early mPFC glutamate elevations. Selective mediation of
sensitization by a subset of neurons was recently demonstrated in the NAc. Sensitizationinduced increases in AMPA and NMDA receptors were shown in the neurons associated
with sensitization, but not the ones that were unassociated (Koya et al. 2012). Future
studies examining potential differences in mGluR5 distribution and function on distinct
projection neurons within the mPFC could be useful.
mPFC mGluR5 and NAc Glutamate
Intra-mPFC activation of mGluR5 increased NAc glutamate levels at 21, but not 1
or 7, days withdrawal in sensitized animals. This escalation likely results from two
factors. The first is the reduction in cysteine-glutamate antiporter function that decreases
intra-NAc baseline glutamate levels and is known to occur during late sensitization
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(Baker et al., 2003) and the second is the increased firing of NAc-terminating projections
within the mPFC following mPFC mGluR5 activation.
Evidence suggests alterations in the NAc play a significant role in the loss-ofcontrol over drug-seeking behavior that ultimately leads to relapse. In agreement with
this, a number of studies have uncovered lasting, NAc-specific changes observable
during late, but not early, withdrawal, and many of these adaptations involve glutamate
transmission and plasticity (Churchill et al., 1999; Kourrich et al., 2007; Schumann and
Yaka, 2009). As previously mentioned, sensitization is associated with cocaine-induced
hyperexcitability of mPFC projection neurons in rodents (Ford et al., 2009; Nasif et al.,
2005) (Hu, 2007), and imaging studies in addicts show heightened mPFC activity in
response to cocaine and cocaine-related cues (Goldstein and Volkow, 2011). Taken
together, one might suppose that the combination of low baseline glutamate levels within
the NAc and heightened cocaine-induced mPFC glutamatergic transmission to the NAc
sets the stage for cocaine and cocaine-associated cues to stimulate NAc output, thus
facilitating addictive behavior. Our finding that intra-mPFC mGluR5 activation increases
NAc glutamate levels during late sensitization may suggest mGluR5 contributes to the
hyperexcitability of mPFC pyramidal neurons following repeated cocaine exposure. Our
present data also corroborates our previous finding that mPFC mGluR5 blockade
prevents late, but not early sensitization (Timmer and Steketee, 2012).
mPFC mGluR5 and VTA Glutamate
mPFC mGluR5 activation did not significantly increase glutamate levels in the
VTA in sensitized or control animals. However, we observed that a subset of sensitized
animals showed substantially higher glutamate levels at 7 days withdrawal following
intra-mPFC mGluR5 stimulation, but the extent of variability between the animals that
displayed an increase and those that did not prevented a significant interaction effect.
One interesting aspect of our findings is the lack of a glutamate increase in the
VTA at 21 days abstinence in sensitized rats following intra-mPFC mGluR5 activation.
In the previous two paragraphs, we propose that cocaine-induced alterations in mPFC
mGluR5 may occur earlier in local mPFC projection neurons, and later in projections to
other brain areas. Our data showing that intra-mPFC mGluR5 activation increases NAc
glutamate at 21 days withdrawal in sensitized animals supports this explanation, however
if mGluR5 stimulation induces greater excitation of extra-mPFC mGluR5-bearing
projection neurons during late sensitization, one might expect a concomitant increase in
VTA glutamate levels. One possible reason why we did not observe a glutamate increase
in the VTA is because mPFC projections to this region did not become more excitable
following mGluR5 stimulation, or glutamate increases in the VTA were too small to
measure. However, as previously mentioned, we did observe increased VTA glutamate
following intra-mPFC mGluR5 activation in roughly half of sensitized animals at 7 days
withdrawal, suggesting alterations in mPFC mGluR5 may have occurred on mPFC-VTA
projections during early sensitization. We may not have observed this in all of our
animals due to differences in microdialysis probe placement within the mPFC or VTA, or
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the degree of sensitization within the animals, which is known to vary (Hooks et al.,
1991). In support of this, the VTA is thought to be involved with the initiation phase of
sensitization and cocaine-induced alterations demonstrated to occur in this region tend to
be transient (Pierce and Kalivas, 1997; Zhang et al., 1997).
In a previous study, we demonstrated that repeated intra-mPFC mGluR5
stimulation induced a cross-sensitization to cocaine that could be prevented via AMPA
receptor blockade within the VTA prior to mPFC mGluR5 activation. This finding led us
to hypothesize that repeated mPFC mGluR5 stimulation increases VTA glutamatergic
transmission, thus facilitating dopaminergic input from the VTA to the NAc and inducing
sensitization. Based on these results, glutamate increases in the VTA following mPFC
mGluR5 activation might be expected in saline control animals. One potential reason
why we did not observe an increase is that while mPFC mGluR5 activation induces
glutamate release in the VTA sufficient to activate dopaminergic projection neurons, the
glutamate fluctuations are too slight to measure via microdialysis. A second possibility is
that intra-mPFC mGluR5 activation increases VTA glutamate to a greater extent with
each successive application of the agonist. Perhaps we would have observed an increase
in VTA glutamate levels following intra-mPFC mGluR5 activation if we measured the
levels over the course of several days.
Conclusions
Data from the present study show mPFC mGluR5 activation increases mPFC
glutamate levels during early, and NAc glutamate levels during late, sensitization.
Excitatory input from the mPFC to the NAc is necessary for the expression of
sensitization (Pierce et al., 1998) (Steketee, 2003) and mPFC projection neurons are
hyperexcitable in response to cocaine following sensitization (Nasif et al., 2005) (Ford et
al., 2009; Hu, 2007)). mGluR5 is a modulatory receptor that has been shown to increase
firing frequency in mPFC pyramidal neurons (Fitzjohn et al., 1999; Marek and Zhang,
2008; Marino et al., 2001) (Homayoun and Moghaddam, 2010). Our results indicate
mGluR5 within the mPFC increases firing of mPFC-Nac projections during late
sensitization, pointing to a role for mGluR5 in sensitization-affiliated neuronal
hyperexcitability in the mPFC. Our data showing an mGluR5-mediated mPFC glutamate
increase at 7 days withdrawal may suggest early changes in the excitability of local
mPFC projections that are transient, but influential in shaping later alterations in NAc
projection neurons.
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Chapter 4. Role of Metabotropic Glutamate Receptor 5 in the Medial Prefrontal
Cortex on Drug-Seeking Behavior
Introduction
Cocaine addiction carries a notoriously high risk of relapse, even following years
of abstinence. Consequently, the discovery of ways to prevent relapse is the predominant
goal of addiction research. There is increasing evidence that mGluR5 modulation may
attenuate the risk of relapse. Systemic administration of an mGluR5 antagonist dosedependently decreased cue- and cocaine-induced reinstatement (Backstrom and Hyytia,
2006; Kumaresan et al., 2009) and it has been suggested the effect of mGluR5
antagonism on cocaine self-administration results from an mGluR5-mediated decrease in
the rewarding properties of cocaine (Kenny et al., 2005; Platt et al., 2008). A primary
way in which mGluR5 antagonism could attenuate the rewarding effects of cocaine is by
reducing transmission through the mesocorticolimbic circuit. Within the mPFC, mGluR5
is primarily located postsynaptically on pyramidal projection neurons that terminate in
reward-associated regions such as the VTA and NAc, and the activation of mPFC
mGluR5 has been shown to increase neuronal excitability (Homayoun and Moghaddam,
2010; Kew and Kemp, 2005). Evidence suggests cocaine sensitization leads to increased
cocaine-induced excitability of mPFC pyramidal neurons (Nasif et al., 2005), a
consequence of which might be increased glutamatergic input to the VTA and NAc. One
might expect that if mPFC mGluR5 activation increased neuronal activity in sensitized
animals, intra-mPFC mGluR5 blockade would prevent and intra-mPFC mGluR5
stimulation would facilitate behavioral and neurochemical indicators of addiction. In
support of this, we previously demonstrated that intra-mPFC mGluR5 blockade
prevented late expression (Timmer and Steketee, 2012) and intra-mPFC mGluR5
activation increased glutamate levels in the NAc at 21-days withdrawal in sensitized
animals (Chapter 3). We consequently became interested in the relationship between
mPFC mGluR5 and drug-seeking, a behavior that can be initiated by cocaine or
associated cues and that, most importantly, precedes relapse
Both contingent and noncontingent models of addiction have yielded a great deal
of information over the past few decades, however, there has been some debate over the
validity of noncontingent methods. Conversely, while it is not without its flaws (Epstein
et al., 2006), the self-administration model possesses more “real-world” attributes of
addiction because the animal is choosing to take the drug rather than receiving it from the
experimenter. However, self-administration experiments can be more time-consuming
and cumbersome than noncontingent studies of sensitization. Therefore, an ideal strategy
would be to employ noncontingent methods as a first-pass screening for prospective
influential factors in addiction and, if a relationship is found, contingent experiments may
follow. Thus, an ancillary inquiry within this study is whether our previous results
obtained with a noncontingent method are consistent with our current findings.
Therefore, in the present study, we investigated in a self-administration paradigm
the effect of mPFC mGluR5 blockade on cue- and drug-induced drug seeking behavior
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following extended cocaine withdrawal. Our results indicate a nonsignificant trend
towards an attenuation of cue-induced, but not drug-induced, drug-seeking following
mPFC mGluR5 blockade.
Methods
Animals and Surgery
Male Sprague-Dawley (Harlan, Indianapolis, IN) rats weighing 275-300 g at the
time of surgery were housed under a reverse 12 h light/dark cycle and had ad libitum
access to food and water. Animals were anesthetized with a ketamine (80
mg/kg)/xylazine (6.0 mg/kg) cocktail (1.0 ml/kg, i.p.). Jugular catheters were composed
of an injection pedestal (Plastics One) bent to 90 degrees and attached to silastic tubing.
The pedestal was affixed to hernia meshing via dental acrylic (Jet-Set, Lang Dental,
Germany). The back-mounted catheters were threaded into the jugular vein and lowered
to a point just above the heart. Following insertion, heparinized saline was injected
through the pedestal to confirm clarity and animals were given Rimadyl (1ml/kg, i.p.).
Immediately following catheterization surgery, animals heads were placed in a
stereotaxic frame (Kopf Instruments) and bilateral cannulae (25 gauge, 14 mm, stainless
steel) were inserted 1 mm above the mPFC (A/P+3.3 mm; M/L+.6 mm; D/V -3.5 mm).
Obturators (32 gauge, 14 mm, stainless steel) were implanted in the cannulae to prevent
occlusion. Animals were given at least one week of recovery time prior to the
commencement of experiments. Procedures were carried out in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and all experiments were approved by
the University of Tennessee Health Science Center Animal Resource Advisory
Committee.
Cocaine Self-Administration Training
Rats were trained to self-administer cocaine via lever-press in an operant box
(Med Associates) containing 2 levers (active and inactive) and 2 cue lights. Animals were
first trained under a FR1 schedule that increased to FR2 once criterion (9 correct
responses) was met. Once FR2 criterion (18 correct responses) was met, the schedule
increased to FR5 and continued as such for the remainder of the training phase. 0.05 mL
of cocaine (0.25 mg) was delivered over the course of 1 second in response to the correct
number of lever presses on the active lever in the presence of the cue light. The training
session ended after 3 hr or 9, 18 or 29 infusions for the FR1, FR2 and FR5 schedules,
respectively. Animals were trained every day for ten days and considered to have learned
the task if 29 infusions were obtained for at least the final 3 days of training. Animals that
did not meet this criteria were excluded from the study. After the final training day,
animals returned to their home cages for 21 days.
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Microinjections
Intra-mPFC microinjections were made using stainless steel injectors (32 gauge,
15 mm) connected via PE20 tubing to 1 uL syringes attached to an injector pump (Sage
Instruments) that delivered drug at the rate of 5 uL/min. After 21 days abstinence,
animals were tested for 4 consecutive days. On day 1, animals received an intra-mPFC
microinjection (15 mm, 32 gauge) of mGluR5-antagonist MTEP (15 nmol/side) or saline
and were placed in the operant boxes wherein lever-presses were recorded for 1 hr. On
day 2, animals received an intra-mPFC microinjection of MTEP or saline (determined by
which one was not received on day 1) and were placed in the operant chambers where
lever-presses were recorded for 1 hr. On day 3, animals received an intra-mPFC
microinjection of MTEP or saline followed by a systemic cocaine injection (15 mg/kg,
i.p.). After receiving cocaine, rats were immediately placed in the chambers for 1 hr and
lever-presses were recorded. On day 4, animals received an intra-mPFC microinjection of
MTEP or saline (dependent on which was not administered on day 3) followed by a
systemic cocaine injection (15 mg/kg, i.p.). Immediately after receiving the cocaine
injection, animals were placed in the boxes for 1 hr and lever-pressing was recorded. The
order of microinjection treatment (saline/MTEP) was counterbalanced.
Histology and Statistics
At the end of experiments, animals were deeply anesthetized with sodium
pentothal (333 mg/kg) and transcardially perfused with 50 mL phosphate-buffered saline
followed by 50 mL 10% paraformaldehyde. Brains were removed from the skull cavity
and placed in formaldehyde-filled vials for at least a week. Brains were then sliced into
100 micron sections, mounted onto gelatin-coated slides and stained with cresyl violet.
Injector placement was then verified via light microscopy using a rat brain atlas (Paxinos
and Watson 1997). Animals with injector placements outside of the mPFC were excluded
from the analysis.
Lever-presses recorded in MTEP and saline conditions on Day 1 and 2 (cueinduced drug-seeking) were compared using a paired t-test. Lever-presses recorded in
MTEP and saline conditions on Day 3 and 4 (drug-induced drug-seeking) were compared
using an paired t-test.
Drugs
Cocaine hydrochloride (Sigma Chemical, St. Louis, MO) and MTEP ((3((2methyl-4-thiazolyl)ethynyl)pyridine hydrochloride), TOCRIS Bioscience, Ellisville, MO)
were diluted with isotonic saline (0.9 units sodium chloride). The dose of MTEP (30
mM) was chosen based on previous experiments (Timmer and Steketee 2012)
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Results
Repeated Training Increased Cue-Induced Cocaine Self-Administration
Animals were trained to lever-press for cocaine for 10 days, a time period
sufficient to facilitate learning based on previous literature. Figure 12 shows mean
responses (lever-presses) over the 10 training days. All animals included in the study
increased active lever responding to the maximum number of responses (145 correct
lever-presses) within a FR5 schedule and maintained that response level for at least the
last 3 days of training.
Effect of Intra-mPFC mGluR5 Blockade on Cue-Induced Drug-Seeking
We hypothesized that intra-mPFC MTEP infusion would attenuate drug-seeking
behavior, as measured by the number of responses (lever-presses), based on our previous
data demonstrating that mPFC mGluR5 blockade prevented late expression. Figure 13
shows the mean number of responses from animals when given intra-mPFC saline and
MTEP. A nonsignificant trend toward an MTEP-induced reduction in responding was
observed (t=2.133, p=0.07).
Effect of Intra-mPFC mGluR5 Blockade on Cocaine-Induced Drug-Seeking
Our previous data demonstrate a reduction in locomotor response to cocaine
following intra-mPFC MTEP administration during late expression (Timmer and
Steketee 2012). Figure 14 shows the mean responses of animals when given an intramPFC microinjection of saline or MTEP followed by a systemic injection of cocaine (15
mg/kg, i.p.). No significant differences were found following analysis with a paired t test.
Differential Effect of mPFC mGluR5 Blockade on High- and Low-Responding Rats
We observed that, when given intra-mPFC saline, roughly half of our animals
exhibited a high response rate (>50 lever-presses) while the other half displayed a lower
response rate (<50 lever-presses). On account of data suggesting intrinsic differences
between “high-responders” and “low-responders”(Flagel et al., 2009), we segregated and
reanalyzed our data based on these categories. Figure 15 shows mean responses of highresponding (a) and low-responding (b) rats when given an intra-mPFC microinjection of
saline or MTEP. MTEP significantly reduced cue-induced responding in high-responding
(t=3.277, p<.05), but not low-responding (t=0.1628, p=0.88), animals. Figure 16 shows
mean responses of high-responding (a) and low-responding (b) animals when given an
intra-mPFC microinjection of saline or MTEP followed by systemic cocaine (15mg/kg,
i.p.). No significant differences were observed between the groups.
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Figure 12. Effect of Self-Administration Training on Responses. Mean responses on
active lever from animals (n=8). Over the 10-day training period, responses increased to
the FR5 criterion of 145 lever-presses per session.
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Figure 13. Effect of Intra-mPFC mGluR5 Activation on Cue-Induced Drug-Seeking.
Mean responses (lever-presses) of animals (n=8) given an intra-mPFC injection of saline
and MTEP are shown.
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Figure 14. Effect of Intra-mPFC mGluR5 Activation on Cocaine-Induced DrugSeeking. Mean responses (lever-presses) from animals (n=8) given an intra-mPFC
microinjection of saline and MTEP followed by systemic cocaine (15 mg/kg, i.p.) are
shown.
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Figure 15. Effect of Intra-mPFC mGluR5 Activation on Cue-Induced Drug-Seeking
on High- and Low-Responding Rats. Mean responses (lever-presses) of highresponding (>50 saline, n=4) (a) and low-responding (<50 saline, n=4) (b) rats in
response to a cocaine-associated cue following an intra-mPFC microinjection of saline or
MTEP. *=p<0.05.
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Figure 16. Effect of Intra-mPFC mGluR5 Activation on Cocaine-Induced DrugSeeking on High- and Low-Responding Rats. Mean responses (lever-presses) of highresponding (>50 saline, n=5) (a) and low-responding (<50 saline, n=3) (b) rats in
response to an intra-mPFC microinjection of saline or MTEP followed by systemic
cocaine (15mg/kg, i.p.).
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Discussion
The present study examined the role of mPFC mGluR5 in cue- and cocaineinduced drug-seeking. The data demonstrate that mPFC mGluR5 blockade may attenuate
cue-induced drug-seeking, but does not affect cocaine-induced drug seeking. Further,
intra-mPFC mGluR5 blockade differentially affected cue-induced drug-seeking in highresponding and low-responding animals.
We previously demonstrated that intra-mPFC mGluR5 antagonism via MTEP
significantly reduced the expression of locomotor sensitization at 21-days withdrawal.
Thus, we were curious whether MTEP would produce any discernable decrease in drugseeking behavior at this time point. In the present study, intra-mPFC mGluR5 blockade
facilitated a nonsignificant decrease in cue-induced drug-seeking. Moreover, while the
previous MTEP-induced reduction in sensitization followed a cocaine injection, the
present data show no effect of MTEP on drug-seeking behavior following cocaine
administration. Several explanations for our findings are explored below.
One possible reason for the decrease in the MTEP-mediated effect on drugseeking relative to sensitization could be the design of our self-administration
experiments. Prior to cocaine self-administration training, it is common for animals to be
trained to self-administer food pellets in the same chambers where they will later
administer cocaine. Food training can result in greater acquisition rates in cocaine
training, and possibly a more robust association between the task and a reward (Koob et
al 2007). We did not train our animals to lever-press for food prior to cocaine training.
While our animals displayed strong and stable acquisition rates (Figure 12), it is possible
that their training was not as robust as it would have been had they been food-trained,
especially after a 21-day lapse.
Perhaps the most interesting aspect of our data is the discrepancy in the effect of
MTEP on drug-seeking in high- and low-responding animals. Some of the animals in our
study responded at relatively low levels on Days 1 and 2 (cue-induced test), and while
responding was generally decreased in these animals following MTEP, the difference in
responding between MTEP and saline conditions was not substantial because of the
overall low level of response. By contrast, on Days 3 and 4 (cocaine-induced test), some
of the previously low-responding animals drastically increased their responding
following cocaine administration. One possible explanation, as described in the previous
paragraph, is that task learning in some animals was not robust enough for the cue alone
to generate the combination of drug-wanting and task- remembering necessary for a high
response rate. However, following cocaine administration, drug-wanting dramatically
increased and the memory of acquiring the drug was enhanced (Saunders and Robinson,
2011), which resulted in a higher response rate. Differences between saline and MTEP
conditions in cue-induced drug-seeking may have been more apparent in our lowresponding animals if we took measures to ensure they acquired a strong association
between the cue and cocaine.
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Alternatively, the difference we observed between high- and low-responding
animals may have resulted from cue-strength variation suggested to occur in rodents
(Meyer et al., 2012). In addicted animals, the cocaine-associated cue is thought to acquire
an incentive salience that presumably facilitates drug-wanting and drug-seeking.
However, recent studies suggest the cue does not become intrinsically rewarding to all
animals and those animals that do not find the cue itself rewarding may be less vulnerable
to addiction (Flagel et al., 2009)). It is possible that the low-responding animals in our
study were not as motivated by the cue as the high-responders and consequently
experienced less drug-wanting than the high-responders. If the high-responders were
then, by this definition, more addicted than the low-responders, this indicates that mPFC
mGluR5 antagonism is effective in reducing drug-seeking in addicted animals. The
significant reduction in cue-induced drug-seeking following intra-mPFC mGluR5
blockade we observed in high-responding animals supports this idea. However, the
resultant low sample size following data segregation and the increase in responses in
previously low-responding animals following cocaine administration precludes us from
being certain our lack of an overall effect results from individual differences in cue
evaluation rather than a learning impairment in low-responding animals. Additional
experiments employing techniques to facilitate more robust learning, such as prior food
training, should be conducted.
A second reason why mPFC mGluR5 blockade may not have exerted a significant
reduction in cue-induced drug-seeking is because the mPFC neuroadaptations that
accompany learning to associate a cue with cocaine may be more extensive than those
affiliated with simply receiving the drug on multiple occasions. In our previous study, we
had proposed that MTEP reduced locomotor sensitization by decreasing the firing of
mPFC pyramidal projection neurons, leading to a decrease in glutamatergic input to the
NAc (Timmer and Steketee, 2012). Perhaps the mPFC plasticity that follows cue-induced
learning serves to increase pyramidal neuronal firing to a greater extent than does the
plasticity that accompanies a noncontingent regime, thus rendering mPFC mGluR5
blockade less effective. If this proves true, the clinical implications of mPFC mGluR5
modulation alone will be decreased, however, a better understanding of the relationship
between cocaine-induced mPFC mGluR5 modifications and other alterations that may
influence excitability could potentially pave the way for an effective pharmacological
means of preventing relapse.
Our data showed that mPFC mGluR5 antagonism did not prevent cocaine-induced
drug-seeking. This finding is somewhat unsurprising, however, because cocaine is a more
potent motivator than a cue alone and previous self-administration studies have failed to
uncover an effect of a manipulation following drug administration, even when the given
manipulation attenuated cue-induced drug-seeking (Pockros et al., 2011)(Chauvet et al.,
2009; Leri et al., 2002). What makes this finding perplexing is the stark inconsistency
with our previous finding of an intra-mPFC MTEP-induced reduction in sensitization
following cocaine administration. One might assume that if cocaine obliterated any effect
of mGluR5 antagonism observed in its absence in a self-administration paradigm, we
would be unlikely to find an effect of intra-mPFC MTEP on sensitization. However, it
should be noted that while our previous finding showed a significant MTEP-induced
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decrease in sensitization, sensitized animals that received MTEP still exhibited greater
locomotion than saline controls, suggesting mPFC mGluR5 antagonism did not
completely block the effects of cocaine. Given the abovementioned suggestion that the
associative learning inherent in a self-administration paradigm induces an mPFC
plasticity more effective at heightening neuronal excitability in the presence of cocaine
and its cues, it is possible that the compounding of that plasticity with cocaine prevented
MTEP from exerting any measurable effect on drug-seeking. Another possibility is that
the effects of intra-mPFC mGluR5 blockade on cocaine-induced drug-seeking may have
been too slight to measure within the self-administration paradigm. Nevertheless, our
data strongly suggest mPFC mGluR5 antagonism does not reduce cocaine-induced drugseeking.
Finally, the implications of this study on the role of sensitization in addiction
research should be addressed. Despite the nonsignificant effect of intra-mPFC mGluR5
antagonism on cue- and drug-induced drug-seeking, the observed trend towards an
MTEP-induced reduction and significant MTEP-induced high-responder reduction in
drug-seeking suggests that mPFC mGluR5 plays a role in addiction, which supports the
usefulness of the simpler noncontingent method as a screening tool for addiction-relevant
factors. As discussed above, the reasons for a lack of a significant overall effect could
result from flaws in experimental design that affected learning, individual differences that
influenced cue-induced motivation, or inherent differences in the plasticity induced by
contingent and noncontingent administration techniques. A future study employing
methods proven to maximize learning and increasing the sample size to acquire more
high-responders might reveal a greater effect of mPFC mGlur5 antagonism on drugseeking, or better describe the differences between high- and low-responding animals. If
not, the combinatorial effect of mPFC mGluR5 blockade and other mPFC manipulations
could be explored.
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Chapter 5. General Discussion
Summary of Findings
Chapter 2
Repeated intra-mPFC administration of Group I agonist DHPG induced crosssensitization to cocaine. This cross sensitization could be prevented via co-administration
of mGluR5 antagonist MTEP, suggesting it was mediated by mGluR5 rather than
mGluR1. Intra-mPFC DHPG-induced cross-sensitization could also be prevented by
intra-VTA injections of AMPA receptor antagonist CNQX administered immediately
prior to intra-mPFC DHPG, indicating dependence on VTA glutamatergic transmission.
mPFC mGluR5 antagonism did not prevent the initiation of sensitization, or the early (7
days withdrawal) expression of sensitization. However, intra-mPFC mGluR5 blockade
did significantly attenuate late (21 days withdrawal) expression, suggesting alterations in
mPFC mGluR5 may represent a lasting adaptation brought on by repeated cocaine
exposure.
Chapter 3
Rats received daily systemic cocaine (15mg/kg i.p.) or saline injections for 4
consecutive days. One, 7, or 21 days from the last injection, an in vivo reverse
microdialysis experiment was conducted wherein 3 escalating concentrations (0.05 uM,
5uM, 50uM) of Group I mGluR agonist DHPG were infused into the mPFC and samples
were collected from the mPFC and NAc or the mPFC and VTA for later analysis of
glutamate concentration. Results showed intra-mPFC DHPG increased mPFC glutamate
levels at 7 days withdrawal, and NAc glutamate levels at 21 days withdrawal in
sensitized, but not control, animals. These findings suggest mPFC mGluR5 activation
may contribute to increased excitatory input from the mPFC to the NAc during late
sensitization. Our data also indicate that early sensitization-induced mGluR5 alterations
in local mPFC neurons may set the stage for later changes in NAc-projecting, mGluR5bearing neurons within the mPFC.
Chapter 4
Animals were trained to self-administer cocaine in an operant box for 10
consecutive days. At the conclusion of training, rats were returned to their home cages for
21 days. Following this withdrawal period, the effect of intra-mPFC blockade via
mGluR5 antagonist MTEP on cue- and cocaine-induced drug-seeking was assessed. We
observed a nonsignificant trend towards decreased cue-induced drug-seeking following
MTEP relative to saline, and no effect of MTEP on cocaine-induced drug-seeking.
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General Discussion
Cocaine addicts experience a lifelong struggle to control drug-seeking behavior and
many relapse, even after years of withdrawal. Therefore, the overarching goal of
addiction research is to understand the mechanisms that contribute to relapse. Imaging
studies in cocaine addicts have revealed increased mPFC activity in response to cocaine
and related cues, and decreased mPFC activity in response to other stimuli (Goldstein and
Volkow, 2011). Similarly, non-human studies have demonstrated increased cocaineinduced excitability of mPFC pyramidal neurons in sensitized animals, a phenomenon
that might ultimately result in increased excitatory input to reward-associated brain
regions, such as the NAc. Furthermore, given the role of the mPFC in excutive functions,
increased mPFC responsiveness to cocaine and its cues at the expense of non-drug
information may contribute to the seemingly irrational and sometimes self-destructive
decisions an addict will make to obtain cocaine. Consequently, an understanding of the
processes that give rise to the mPFC excitability that follows repeated cocaine exposure
may open new doors for lessening the risk of relapse.
The data from the present studies suggest mPFC mGluR5 contributes to the
regulation of the excitability of mPFC projections to the NAc during late, but not early,
sensitization. We first showed that intra-mPFC blockade significantly attenuated the
locomotor response to cocaine in sensitized rats at 21, but not 7, days withdrawal. Then,
we observed increased NAc glutamate levels following mPFC mGluR5 activation at 21
days withdrawal in sensitized animals. Finally, we noted a nonsignificant trend towards a
reduction in cue-induced drug-seeking following intra-mPFC mGluR5 antagonism at 21
days withdrawal.
The key finding from our first set of experiments (chapter 2) was the reduction in
late expression following mPFC mGluR5 blockade, however, the failure of intra-mPFC
mGluR5 blockade to prevent early expression was somewhat puzzling. One explanation
we offered at the time was that cocaine-induced mPFC glutamate levels were too high to
reveal an effect of mGluR5 blockade during early expression. A second possibility we
proposed was that, due to alterations in mGluR5 itself or other late-sensitizationassociated cellular changes, mGluR5 activation was more influential over mPFC
neuronal output during late sensitization. Results from our second set of experiments
(chapter 3) suggest the latter explanation may be more accurate because we observed a
glutamate increase in the NAc following mPFC mGluR5 stimulation during late, but not
early, expression. Future studies could explore potential changes in mGluR5-bearing
NAc projections within the mPFC from early to late expression.
An interesting question our findings raise is whether and how early changes in the
mPFC glutamate system give rise to later alterations in communication between the
mPFC and other regions, such as the NAc. We showed that mPFC mGluR5 activation
increased mPFC glutamate levels at 7 days withdrawal in sensitized animals, an effect
that was not present during late sensitization. As previously discussed, repeated cocaine
exposure may induce alterations in mGluR5-bearing local mPFC projections earlier than
in neurons that project to other brain regions. As is the case with mGluR5 alterations that
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are associated with late sensitization, we do not know whether mGluR5 is altered in local
projections during early sensitization or if other cellular properties are changed in a way
that makes mGluR5 activation more likely to increase firing. Nonetheless, it is possible
that early mGluR5-associated changes could represent a critical step in more permanent
mGluR5-affiliated alterations in mPFC projection neurons. Differences in mGluR5
presence and activity in local and NAc-projecting mPFC neurons could be explored in
the future, as could related alterations that may potentially affect the influence of
mGluR5 over neuronal excitability.
The significant decrease in late expression and the nonsignificant but notable
reduction in cue-induced drug-seeking observed in animals following intra-mPFC
mGluR5 blockade suggests mPFC mGluR5 is involved with processes that mediate longterm cocaine addiction. While we did not observe an effect of mPFC mGluR5
antagonism on cocaine-induced drug-seeking, our data still suggest that mPFC mGluR5
antagonism reduces the influence of cocaine and related cues on addictive behavior. That
said, as discussed earlier, further studies employing the self-administration paradigm
should be conducted in a manner than maximizes task acquisition and contains a sample
size sufficient to yield a suitable number of high-responding animals. Such an experiment
will shed light on whether the failure of mPFC mGluR5 antagonism to significantly
reduce cue-induced drug-seeking resulted from experimental design, individual
differences or the lack of a substantial role of mGluR5 in drug-seeking.
An ancillary objective of our self-administration experiments was to assess the
congruency of findings obtained using a contingent and a noncontingent method. As
previously discussed, the discrepancy in drug administration that exists between the
noncontingent method and the process addicts undergo while becoming dependent on
cocaine has called into question the usefulness of the noncontingent method in addiction
research. Since our data collected using a contingent method showed a nonsignificant
reduction in cue-induced drug-seeking following intra-mPFC mGluR5 antagonism that
may be more pronounced under different experimental conditions, and our data obtained
using a noncontingent methods showed an mPFC mGluR5-mediated reduction in late
expression, a substantial degree of similarity appears to exist. Given the simplicity and
straightforwardness of the noncontingent method, its employment as a screening
technique performed prior to more involved experiments seems suitable.
Taken together, our experiments are the first to explore the role of mPFC mGluR5
in cocaine addiction and our data suggest this receptor may contribute to the enhanced
excitability of sensitized mPFC pyramidal cells. Given that the effects of intra-mPFC
mGluR5 manipulations were observable during late sensitization, alterations in mPFC
mGluR5 may represent a lasting neuroadaptation brought on by repeated cocaine
exposure.
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